ПРИМЕНЕНИЕ МОДИФИЦИРОВАННЫХ ПОЛЫХ ВОЛОКНИСТЫХ МАТЕРИАЛОВ ДЛЯ УДАЛЕНИЯ ЭКЗОТОКСИНОВ, ВЫРАБАТЫВАЕМЫХ Escherichia coli, ИЗ ЖИДКОСТЕЙ, ПРЕИМУЩЕСТВЕННО ИЗ КРОВИ И ПЛАЗМЫ, А ТАКЖЕ ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ СОПУТСТВУЮЩИХ ЗАБОЛЕВАНИЙ

Настоящее изобретение относится к химически модифицированным полым волокнистым материалам для экстракорпорального удаления экзотоксинов, вырабатываемых патогенной Escherichia coli, из содержащих белок жидкостей. Вещество содержит модифицированные полые волокнистые материалы, выбранные из группы, состоящей из полиамида, полисульфона, простого полиэфира, полиэтилена, полипропилена, сложного полиэфира и их производных и/или смесей. Упомянутые полые волокнистые материалы модифицированы и содержат щупальца, включающие анионообменные группы, где анионообменные группы содержат по меньшей мере одну группу, состоящую из синтетических поликатионных цепей и полусинтетических поликатионных цепей и природных поликатионных цепей, где указанные синтетические, полусинтетические и природные поликатионные цепи линейные или разветвленные. Изобретение обеспечивает эффективное удаление токсинов из крови или плазмы, что позволяет его использовать при лечении пациентов, страдающих от заболеваний, которые вызваны ...

СПЕЦИФИЧЕСКИЙ ДЛЯ ПАЦИЕНТА ИММУНОАДСОРБЕНТ ДЛЯ ЭКСТРАКОРПОРАЛЬНОГО АФЕРЕЗА И СПОСОБ ЕГО ПОЛУЧЕНИЯ

Изобретение может быть использовано в медицине для лечения аутоиммунных заболеваний. Заявлен иммуноадсорбент для экстракорпорального афереза, специфический для каждого пациента. Он состоит из антигенов и антител, ковалентно связанных с активированным биосовместимым твердым материалом-носителем. Антигены и антитела получены путем расщепления иммунокомплексов, изолированных из крови или других жидкостей тела того же самого пациента, для которого данный иммуноадсорбент предназначен. Способ получения иммуноадсорбента включает выделение иммунокомплексов из крови и/или других жидкостей тела пациента, очистку их и расщепление на антитела и антигены и ковалентное связывание их с активированным биосовместимым материалом-носителем. Изобретение позволяет лечить хронические формы аутоиммунных заболеваний и заболеваний, связанных с дизрегулированием иммунной системы. При этом исключается опасность передачи возбудителей таких заболеваний, как ВИЧ и гепатит. 2 с. и 5 з.п. ф-лы, 7 ил., 7 табл.

СИСТЕМА КОРРЕКЦИИ БИОЛОГИЧЕСКОЙ ЖИДКОСТИ

Изобретение относится к биологии и медицине и может быть применено для очистки биологических жидкостей и приведения их состава к физиологическим нормам. Система коррекции биологической жидкости включает связанные с помощью шлангов с установленными в них клапанами, установленными с возможностью обеспечения прохождения через систему биологической жидкости от входного штуцера к выходному, герметичные: емкость для магнитоуправляемого сорбента (МУСа), камеры смешивания МУСа с биологической жидкостью и осаждения МУСа из этой жидкости и фильтрующее устройство, через выходной проток системы соединенное с выходным штуцером, связанным со входным протоком системы, камеры смешивания и осаждения МУСа и емкость для МУСа выполнены с возможностью изменения своих объемов и снабжены приводом, причем камеры смешивания МУСа с биологической жидкостью и осаждения МУСа из этой жидкости выполнены в виде емкостей, имеющих общие днище и крышку, при этом камеры выполнены имеющими также общую прикрепленную к днищу ...

СЕЛЕКТИВНАЯ МОДУЛЯЦИЯ ХЕМОКИНОВ

... 1. Применение металла или оксида металла для изготовлении лекарственного средства для лечения или предотвращения заболевания, характеризующегося нежелательной экспрессией и/или высвобождением индуцируемого интерфероном-γ белка массой 10 кДа, IP-10, в субъекте, где указанный металл выбран из металла группы IV или V Периодической системы элементов. ! 2. Применение по п.1, где указанное лекарственное средство лечит или предотвращает указанное заболевание удалением IP-10 в указанном субъекте. ! 3. Применение по п.1 или 2, где указанное заболевание выбрано из группы, состоящей из инфекционного заболевания, нежелательной воспалительной реакции или реакции «трансплантат против хозяина», характеризующихся нежелательной экспрессией и/или высвобождением IP-10 в указанном субъекте. ! 4. Применение по п.3, где указанным инфекционным заболеванием является вирусное инфекционное заболевание. ! 5. Применение по п.3, где указанной нежелательной воспалительной реакцией является аутоиммунное заболевание.

МАТЕРИАЛ ДЛЯ ОЧИСТКИ КРОВИ

АГОНИСТИЧЕСКИЕ АУТОАНТИТЕЛА К α- И β-АДРЕНЕРГИЧЕСКИМ РЕЦЕПТОРАМ ПРИ БОЛЕЗНИ АЛЬЦГЕЙМЕРА И СОСУДИСТОЙ ДЕМЕНЦИИ

... 1. Пептид, состоящий из:(i) аминокислотной последовательности SEQ ID NO 1: LGYWAFGRVFCN или SEQID NO 2: PAPEDETICQINEE);(ii) аминокислотной последовательности, идентичной аминокислотной последовательности (i) на 70%, предпочтительно на 80% или более предпочтительно на 90% или 95%;(iii) аминокислотной последовательности (i) или (ii), модифицированной путем разветвления или удлинения с помощью одного и того же или другого пептида аминокислотной последовательности (i) или (ii) с образованием гомоолигомерного или гетероолигомерного пептида,посредством чего любой конец пептида последовательностей (i)-(iii) имеет дополнительную группу, выбранную из аминовой, амидной, ацетильной, биотиновой, детиобиотиновой групп, маркера, спейсера, линкера, GKK, SGKK, или не имеет дополнительной группы.2. Пептид по п. 1 для применения в медицинской диагностике или в качестве лекарственного средства.3. Пептид по п. 1 или 2, отличающийся тем, что он связывается с антителами страдающих деменцией пациентов, предпочтительно ...

ИСПОЛЬЗОВАНИЕ ГЕМОСОВМЕСТИМОГО СОРБЕНТА ИЗ ПОРИСТЫХ ПОЛИМЕРНЫХ ШАРИКОВ ДЛЯ УДАЛЕНИЯ ВЫЗЫВАЮЩИХ ЭНДОТОКСИКОЗ МОЛЕКУЛ

СИСТЕМА КОРРЕКЦИИ БИОЛОГИЧЕСКОЙ ЖИДКОСТИ

... 1. Система коррекции биологической жидкости, включающая связанные с помощью шлангов-протоков с установленными в них с возможностью обеспечения прохождения через систему биологической жидкости от входного штуцера к выходному клапанами, герметичные: емкость для магнито-управляемого сорбента (МУСа), камеры смешивания МУСа с биологической жидкостью и осаждения МУСа из этой жидкости и фильтрующее устройство, соединенное с выходным протоком камеры осаждения, и с выходным штуцером системы, отличающаяся тем, что камеры смешивания и осаждения МУСа и емкость для МУСа выполнены с возможностью изменения своих объемов и снабжены соответствующим приводом, причем камеры смешивания МУСа с биологической жидкостью и осаждения МУСа из этой жидкости выполнены в виде емкостей, имеющих днище, общую крышку, а также общую, прикрепленную к днищу этих камер стенку - межкамерную перегородку и соединены через проток в этой перегородке с установленным в нем клапаном, причем на других боковых стенках этих камер выполнены ...

УЛУЧШЕННОЕ РАЗДЕЛЕНИЕ

... 1. Способ для селективного связывания и выделения, по меньшей мере, одного компонента из телесной жидкости (жидкости организма), включающий в себя прохождение телесной жидкости, такой как цельная кровь, через жесткую интегральную разделительную матрицу, без исключения компонентов по размерам из указанной матрицы, причем указанная матрица имеет пористую структуру с размером пор в пределах от 5 до 500 мкм, а также активную поверхность в пределах от 0,5 см2 до 10 м2, связывание, по меньшей мере, одного компонента телесной жидкости, по меньшей мере, с одной функциональной группой, расположенной в указанной матрице, при этом указанную матрицу получают с помощью способа, выбранного из группы, включающей в себя способы спекания, формования и вспенивания. 2. Способ по п.1, включающий в себя нанесение покрытия или модификацию поверхности указанной пористой структуры указанной матрицы для размещения, указанной, по меньшей мере, одной функциональной группы на указанной пористой структуре, за счет ...

Способ получения сферического углеродного биоадсорбента

Tumour necrosis factor-alpha and/or bacterial lipo-poly:saccharide removal

Extracorporeal removal of tumour necrosis factor- alpha (TNF- alpha ) and/'or bacterial lipopolysaccharides (LPS, endotoxin) from whole blood and/or blood plasma is carried out with a perfusion system contg. cationic and anionic exchange material. Also claimed is a device based on this technique for the treatment of patient blood and/or plasma and which is capable of simultaneous removal of TNF- alpha and LPS is described.

Hochwirksame Abtrennung von lipoproteinischem Cholesterol niedriger Dichte aus Vollblut

COMPUTER-CONTROLLED MEDICAL CARE SYSTEM

Gerät zur Modifikation einer Plasmazusammensetzung und Remodellierung.

ADSORBER FOR HAEMOPERFUSION

METHOD FOR REMOVING UREMIC WASTES FROM DIALYSING FLUID IN AN ARTIFICIAL KIDNEY

... 1461634 Purifying dialysing fluid TAKEDA YAKUHIN KOGYO KK 27 Feb 1974 [27 Feb 1973] 8853/74 Heading B1X Uremic wastes are removed from dialysing fluid in an artificial kidney of the recycle type by treating artificial kidney dialysing fluid with activated carbon and gel-type alumina. The dialysate may be treated with a mixture of the carbon and alumina, or successively with the carbon and alumina or the alumina and the carbon e.g. packed in respective columns. The gel-type alumina may comprise up to 30% by weight of silica, based on the total weight. Reference has been directed by the comptroller to Specification 1406133.

ENDOTOXIN REMOVAL

AGENTS FOR REMOVING HUMAN IMMUNODEFICIENCY VIRUS & RELATED COMPOUNDS

ADSORBENT COMPOSED OF POROUS BEADS OF CHITOSAN AND ADSORPTION METHOD USING SAME

METHOD AND APPARATUS FOR THE TREATMENT OF AUTOIMMUNE AND ALLERGIC DISEASES

Column for adsorption of blood proteins

A column for adsorption of blood proteins is disclosed which comprises a blood inlet and a blood outlet each with a filter, and a porous material packed between both the filters, which material has a mean pore diameter (D) of 30-3,000 angstroms with the volume occupied by pores with diameters of 0.8 D-1.2 D being at least 80% of the whole pore volume. The adsorption column can eliminate specific blood proteins by selective adsorption and is useful in the treatment of autoimmune diseases and cancer, for instance.

APPARATUS AND METHOD FOR AFFINITY SEPARATION

Apparatus for blood concentration

A disposable blood transfer conduit 13 for use in association with a pump drive unit, a blood collection vessel 11 and a blood concentration device 14, the conduit 13 comprising a blood transfer tube and a peristaltic pump unit 12 having an enclosed housing mounted about the blood transfer tube 13, a first end of the blood transfer conduit being adapted for connection, in use, to the blood collection vessel 11 and a second end of the blood transfer conduit 13 being adapted for connection, in use, to the blood concentration device 14, wherein at least part of the blood transfer tube13 is resiliently deformable and extends through enclosed housing of the peristaltic pump unit 12, and wherein the peristaltic pump unit 12 is adapted for releasable engagement, in use with the pump drive unit to convey blood from the blood collection vessel 11 to the blood concentration device 14.

DIALYSIS DEVICE

Transdermal bioreactor

APHERESE-VORRICHTUNG

APHERESE-VORRICHTUNG

PROCEDURE FOR THE SEPARATION FROM RARE CELLS FROM FLUID SAMPLES

EXTRAKORPORALES BLUT- ODER PLASMAREINIGUNGSSYSTEM

SURFACE-CHANGED DIVINYLBENZENHARZ WITH HÄMOKOMPATIBLER COATING

Kit for prevention or treatment of Alzheimer's disease comprises means for inducing sequestration of amyloid beta in plasma and apheresis apparatus which exhibits an amyloid beta precursor protein receptor

Kit for prevention or treatment of Alzheimer's disease comprises means (M1) for inducing sequestration of amyloid beta in plasma, and apheresis apparatus (A1), containing a solid carrier contactable with blood or plasma fluid, which exhibits an amyloid beta precursor protein (APP) receptor (I). Independent claims are also included for the following: (1) method for the prevention or treatment of Alzheimer's disease comprising administering (M1) and treating the patient with (A1) where APP is removed from the patient's blood by (A1); and (2) use of an amyloid beta mimotope for inclusion in combination therapy comprising (M1) and (A1) for prevention or treatment of Alzheimer's disease. ACTIVITY : Neuroprotective: Nootropic. MECHANISM OF ACTION : None given.

DIALYSIERVORRICHTUNG MIT SELEKTIVER CHEMISCHER AKTIVITAET

ABSORBIERENDES TEILCHENMATERIAL, INSBESONDERE ZUM ENTGIFTEN VON BLUT, UND VERFAHREN ZUR HERSTELLUNG DIESES MATERIALS

ADSORPTION COLUMN FOR THE CLEANING OF BODY FLUIDS

ABSORBING PARTICLE MATERIAL, IN PARTICULAR TO DETOXICATING BLOOD, AND PROCEDURE FOR THE PRODUCTION OF THIS MATERIAL

APHERESE OF LEUKOCYTES FROM BLOOD FOR THE TREATMENT OF HIV

ABSORBING PARTICLE MATERIAL, IN PARTICULAR TO DETOXICATING BLOOD, AND PROCEDURE FOR THE PRODUCTION OF THIS MATERIAL

BAG AND DEFIBRINIERUNGSVERFAHREN USING A TEXTILE ELEMENT

SORPTIONSMITTEL FÜR ENDOTOXINE

The invention relates to a sorbent for removing endotoxins from a biological liquid, the sorbent comprising a water-insoluble, porous support and polymyxin which is immobilized on the support, said support having a neutral, hydrophobic surface and the polymyxin being immobilized on the surface of the support via hydrophobic interaction. The sorbent is especially used in extracorporeal blood purification, especially for the treatment of individuals suffering from a sepsis.

READY FOR USE BLOOD CLEANING AND/OR BLOOD TREATMENT COLUMN

MECHANISM FOR BLOOD CLEANING

SELECTIVE DISTANCE OF IMMUNE COMPLEXES.

CARRIER FOR SELECTIVE ONES IMMUNOREINIGUNG AND PROCEDURES FOR THE TREATMENT OF THIS CARRIER.

DRY ONE, STERILE ONE, GAMMA GLOBULIN TIED UP COLUMN AND PROCEDURE FOR THE PRODUCTION THE SAME.

MATERIAL FOR THE DETOXIKATION OF BODY STRANGERS, TOXIC OF WORKING SUBSTANCES IN THE BLOOD

ADSORBENT WITH DIFFERENTLY MODIFIED SURFACE RANGES, PROCEDURES FOR ITS PRODUCTION AND USE OF IT

IMPROVED SEPARATION

PROCEDURE FOR THE PRESERVATION OF A PROJECTION PARLIAMENTARY GROUP OF ACTIVATED THROMBOZYTEN

PROCEDURE FOR SIMULTANEOUS EXTRAKORPORALEN THE ELIMINATION OF TUMOR NECROSIS FACTOR ALPHA AND BACTERIAL ONE LIPOPOLYSACCHARIDEN FROM FULL BLOOD AND/OR BLOOD PLASMA

DIAPHRAGM AFFINITY SYSTEM AND PROCEDURE FOR ITS USE

PROCEDURE AND DEVICE FOR THE INCREASE AND/OR DECREASE OF THE CONCENTRATION IMMUNMODULATORISCH OF EFFECTIVE MATERIALS IN MATERIAL MIXTURES

SORBENTMITTEL AND ITS MANUFACTURING PROCESSES

Immunoadsorption

Upon administration of r AAV vectors the humoral immune response (neutralizing antibodies) is the first barrier that needs to be overcome. Surprisingly it was found that by using immunoadsorptionfor depletion of immunoglobulinsfrom the blood (plasma), subjects can be highly efficiently treated with rAAV vectors, i.e. obtain highly efficient transduction after rAAV vector administration, in spite of the presence of high levels of nAb.

Reduction of advanced glycation endproducts from bodily fluids

The invention concerns removing advanced glycation end products from a bodily fluid by contacting the bodily fluid with a sorbent.

METHOD FOR TREATING AIDS AND OTHER IMMUNE DEFICIENCIES AND IMMUNE DISORDERS

Use of aptamers in therapy and/or diagnosis of autoimmune diseases

The present invention is directed to an aptamer comprising or consisting of the nucleic acid sequence of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and/or a nucleic acid sequence being at least 80% identical to one of SEQ ID No. 1, 2 and 3 for use in therapy and/or diagnosis of autoimmune diseases, wherein the autoimmune disease is cardiomyopathy, dilated cardiomyopathy (DCM), peripartum cardiomyopathy (PPCM), idiopathic cardiomyopathy, Chagas' cardiomyopathy, Chagas' megacolon, Chagas' megaesophagus, Chagas' neuropathy, benign prostatic hyperplasia, scleroderma, psoriasis, Raynaud syndrome, pre-eclamsia, kidney allograft rejection, myocarditis, glaucoma, hypertension, pulmonary hypertension, malignant hypertension, and/or Alzheimer's disease.

Use of aptamers in therapy and/or diagnosis of autoimmune diseases

The present invention is directed to an aptamer comprising or consisting of the nucleic acid sequence of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and/or a nucleic acid sequence being at least 80% identical to one of SEQ ID No. 1, 2 and 3 for use in therapy and/or diagnosis of autoimmune diseases, wherein the autoimmune disease is cardiomyopathy, dilated cardiomyopathy (DCM), peripartum cardiomyopathy (PPCM), idiopathic cardiomyopathy, Chagas' cardiomyopathy, Chagas' megacolon, Chagas' megaesophagus, Chagas' neuropathy, benign prostatic hyperplasia, scleroderma, psoriasis, Raynaud syndrome, pre-eclamsia, kidney allograft rejection, myocarditis, glaucoma, hypertension, pulmonary hypertension, malignant hypertension, and/or Alzheimer's disease.

A flow system of a dialysis device and a portable dialysis device

Wearable hemoperfusion device

The present technology relates to methods and devices for the removal of toxins and pathogens from infected blood of patients. In particular, devices are designed to be portable, wearable, disposable and self-contained extracorporeal devices that can be easily assembled from a kitln one embodiment, the present invention provides a portable and/or wearable device for extracorporeal removal of a toxin and/or pathogen from blood of an individual infected with a toxin and/or pathogen.

BODY FLUID-PURIFYING APPARATUS

Device and method for the analysis of rolling blood leukocytes

Flow devices for the reduction of compounds from biological compositions and methods of use

METHODS OF MAKING BIOCOMPATIBLE NUCLEOPHILIC MATERIAL

PURIIFYING BLOOD AND PLASMA

MOLECULAR SIEVE ARRANGEMENT

Oligosaccharide supports for e.g. removal of antibodies from blood

Adsorbents for high mobility group proteins and column for purifying body fluid

DIALYSIS APPARATUS WITH SELECTIVE CHEMICAL ACTIVITY

AUTOMATED SYSTEM AND METHOD FOR WITHDRAWING COMPOUNDS FROM BLOOD

Automated systems (10) and methods for withdrawing a selected compound from blood are disclosed. The systems and methods utilize a disposable fluid circuit (50) mounted on a re-usable hardware component or module (12). The system withdraws blood from a donor or patient, separates the blood into two or more components and further combines the separated component with a solvent so as to remove a compound from the blood component.

METHOD FOR REMOVAL OF HIV AND OTHER VIRUSES FROM BLOOD

This invention discloses a method for reducing the viral load by removal of viruses or fragments or components thereof from the blood by extracorporeally circulating blood through hollow fibers which have in the porous exterior surface, immobilized affinity molecules having specificity for viral components. Passage of the fluid through the hollow fibers causes the viral particles to bind to the affinity molecules thereby reducing the viral load in the effluent.

METHOD AND APPARATUS FOR CONTINUOUS REMOVAL OF SUBMICRON SIZED PARTICLES IN A CLOSED LOOP LIQUID FLOW SYSTEM

A method and apparatus for continuous removal of submicron sized artificial oxygen carriers (rAOC) and other materials such as cancer cells and bacteria from blood and other liquids. A centrifuge rotor having a curved shape is offset on a spinning rotor base and creates contiguous areas of low to high centrifugal force depending on the distances from the axis of the rotor base. This creates a density gradient field that separates materials of different densities input to the centrifuge that exit via different outputs. A monitor detects any red blood cells (RBC) with the rAOC before they exit the centrifuge. If there are any RBC detected logic circuitry changes the speed of rotation of the rotor, and the flow rate of pumps inputting and removing separated blood and rAOC to and from the centrifuge until there are no RBC in the rAOC exiting the centrifuge.

REMOVAL OF VIRULENCE FACTORS THROUGH EXTRACORPOREAL THERAPY

A method to remove virulence factors from infected blood by passing the blood through a surface cartridge with immobilized carbohydrates, such as heparin, wherein the virulence factors are toxins released from pathogens such as B. anthracis, S. aureus, and P. aeruginosa.

BLOOD COMPONENT SEPARATION SYSTEM AND SEPARATION MATERIAL

The present invention relates to a separation system and a separation material for easily and rapidly separating a red blood cell-rich fraction, a white blood cell-rich fraction, and/or a platelet-rich fraction from a biological fluid containing these blood cell components without the necessity of performing centrifugation. The separation of a red blood cell-rich fraction, a white blood cell-rich fraction, and/or a platelet-rich fraction from a biological fluid can be accomplished by capturing white blood cells and platelets on a blood cell separation material by contacting the biological fluid with the blood cell separation material, thereby providing a red blood cell-rich fraction; and recovering a white blood cell-rich fraction by separating white blood cells captured from the resulting blood cell separation material using a separation solution.

PURIFICATION APPARATUS AND METHOD EMPLOYING A REGENERABLE LIGAND

There is disclosed a system and apparatus for purifying a fluid stream which employ a fixed ligand to absorb a ligate carried in the fluid stream. The system and apparatus each includes a bed of ligands affixed to a semipermeable membrane. The ligand has a binding constant which, in the environment normally present in the fluid stream, will predictably bind the ligate and thus remove it from the fluid stream. An agent which regenerates the ligand is conveyed to the ligand bed by diffusion across the semipermeable membrane. The diffused agent breaks the ligateligand bond. The ligand is regenerated for subsequent use, and the ligate is freed for disposal.

APPARATUS FOR PURIFYING BLOOD

... of the invention An apparatus for purifying blood which is able to separate blood into plasma and blood rich in blood cells, to purify the separated plasma and to mix the purified plasma into the blood stream simultaneously by itself. The apparatus has two parts, i.e. a blood flowing system in which the blood is separated by means of porous hollow fibers provided in a container and the purified plasma is mixed into the blood stream through the hollow fibers, and a plasma flowing path in which the separated plasma is circulated and purified at a plasma purifying device provided on the way of the path. The apparatus has a simple structure and can be operated without any specific cares and difficulty. The apparatus is free from any problems, for instance, hemolysis, fiber blockage, mixing of the purifier particles into blood, and the like.

FAT EXTRACTION

The invention relates to a process of removing fat from a mammalian body comprising the steps of: extracting blood from said mammalian body, said blood containing solubilised fat; extracting at least a portion of said solubilised fat from the blood; and returning the extracted blood to the mammalian body. The invention also relates to an apparatus for performing the process and a method of treating obesity with the process and apparatus.

BLOOD PURIFICATION DEVICE

SURFACE MODIFIED DIVINYLBENZENE RESIN HAVING A HEMOCOMPATIBLE COATING

... ▓▓▓A polymeric resin is disclosed in the form of beads or particles having a ▓coating thereon which renders the resin blood compatible. The resin comprises ▓divinylbenzene monomer which has a porosity, pore size, and surface area ▓suitable for absorption of unhealthy components of blood, such as .beta.-2-▓microglobulin.▓ ...

IMMUNOGLOBULIN ADSORBENT AND ADSORPTION APPARATUS

IMMUNOADSORPTION

Upon administration of r AAV vectors the humoral immune response (neutralizing antibodies) is the first barrier that needs to be overcome. Surprisingly it was found that by using immunoadsorptionfor depletion of immunoglobulinsfrom the blood (plasma), subjects can be highly efficiently treated with rAAV vectors, i.e. obtain highly efficient transduction after rAAV vector administration, in spite of the presence of high levels of nAb.

IMMUNOSUPPRESSIVE PROTEIN ADSORPTION MATERIAL AND ADSORPTION COLUMN

The purpose of the present disclosure is to provide an adsorbing material in which the physical strength of a carrier material is maintained and immunosuppressive proteins are efficiently adsorbed. The present disclosure provides an immunosuppressive-protein-adsorbing material that includes a water-insoluble carrier to which is bonded one or more nitrogen-containing compounds selected from polyamines represented by a prescribed formula and aliphatic amines represented by a prescribed formula, the total amount of amino groups on the water-insoluble carrier being greater than 0 µmol and no greater than 2500 µmol per gram, and the amount of primary amino groups on the water-insoluble carrier being no greater than 450 µmol per gram.

TREATMENT OF BLOOD WITH OLEAGINOUS SUBSTANCE

APHERESIS DEVICE

The invention relates to an apharesis device for use in the treatment of Alzheimer patients. Said device comprises a solid support with which a flow of blood or plasma can be contacted.

HEMOCATHARTIC METHOD AND HEMOCATHARTIC COLUMN

A method for purifying blood by using a column which is packed with an adsorbent capable of adsorbing and removing components to be removed from blood and through which blood is externally circulated for purification while satisfying the relation (P120/P5)<=1.3 (wherein P120 represents the blood pressure 120 minutes after the initiation of the blood circulation while P5 represents the blood pressure 5 minutes after the initiation of the blood circulation), and an apparatus therefor. In this method, an increase in the blood pressure during the external circulation can be regulated and blood components are scarcely damaged during the circulatory purification.

THERAPEUTIC DETOXIFICATION COMPOSITIONS AND METHODS OF MAKING AND USING SAME

A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.

CYTOPHERESIC CARTRIDGE AND USE THEREOF

The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions within a subject and to related methods. More particularly, the invention relates to a cytopheretic cartridge that includes a housing and, disposed within the housing, a solid support capable of sequestering activated leukocytes and/or platelets.

REMOVAL OF MYOGLOBIN FROM BLOOD AND/OR PHYSIOLOGICAL FLUIDS

A polymer sorbent clears myoglobin from blood and/or other physiological fluids and solutions. Normal saline or human serum in which myoglobin was dissolved is perfused by a peristaltic pump through a column packed with the polymer sorbent. After a four-hour perfusion, the myoglobin level in normal saline fell from initial levels to virtually undetectable levels. Perfusion through the polymer sorbent was then found to lower concentrations of dissolved myoglobin to a significant degree in samples of human serum after four hours, indicating that the polymer sorbent is an effective sorbent for myoglobin.

LIVER SUPPORT SYSTEM

The present disclosure relates to an artificial, extracorporeal system for liver replacement and/or assistance, comprising a liver dialysis device for conducting hemodialysis on a patient suffering from liver failure, which is characterized in that it comprises a first standard hollow fiber membrane dialyzer which does not allow passage of an essential amount of albumin over the membrane wall and which is perfused with the patient's blood, and a second hollow fiber membrane dialyzer which allows the passage of essential but defined amounts of albumin over the membrane wall and which receives the blood of the first standard hemodialyzer and wherein the filtrate space is closed off from the lumen space of the hollow fibers and is populated by adsorbent material which may comprise one or more different adsorbents.

DEVICE AND METHOD FOR THE ANALYSIS OF ROLLING BLOOD LEUKOCYTES AND IDENTIFYING INHIBITORS AND PROMOTERS

... 2110292 9221746 PCTABS00017 The present invention provides in vitro models of the in vivo) rolling and arrest of leukocytes along the endothelial cell wall, which are important steps in the migration of leukocytes out of the blood stream and into tissue, as part of the inflammatory response. The in vitro models of the invention are functional under physiologic flow conditions resulting in physiologic shear stresses. In a specific embodiment, for modelling leukocyte rolling, the apparatus of the invention comprises a solid phase surface with rolling mediator molecules present thereon. Such rolling mediators are, for example, selectins and selectin ligands which have binding partners expressed on leukocytes. In another specific embodiment, for modelling leukocyte rolling followed by adhesion/arrest, the apparatus of the invention comprises a solid phase surface with both rolling mediators and integrin binding partners present thereon. The apparatuses of the invention can be used for collecting ...

DEVICE AND METHOD FOR DEPLETION OF THE LEUCOCYTE CONTENT OF BLOOD AND BLOOD COMPONENTS

Removal of Selected Factors from Whole Blood or Its Components

METHODS AND DEVICES FOR THE REDUCTION OF SMALL ORGANIC COMPOUNDS FROM BLOOD PRODUCTS

Methods and devices for reducing the concentration of small organic compounds in a blood product while substantially maintaining a desired biological activity of the blood product, the device comprising highly porous adsorbent particles, and wherein the adsorbent particles are immobilized by an inert matrix.

Procédé de purification d'une solution conductrice ionique

Vorrichtung zur selektiven Entfernung von Aminosäuren und/oder definierten Proteinen aus Blut

Appareil d'épuration du sang

Method for reducing amyloid beta concentration in blood

The present invention relates to a method for reducing a β-amyloid concentration in blood. Specifically, the present invention relates to a method for reducing a β-amyloid concentration in blood, comprising the steps of; removing blood out of a body, passing the blood that is removed through a hollow fiber membrane, and returning the blood that is passed through into the body, wherein the blood containing a β-amyloid-albumin complex is passed through the hollow fiber membrane to allow β-amyloid to adsorb to the hollow fiber membrane so that the β-amyloid concentration in blood is reduced.

Methods and systems for reducing viral load of hepatitis c virus in hemodialysis patients

The present technology relates to methods and systems for the removal of pathogens and fragments thereof in hemodialysis patients. In particular, methods and systems are described where lectins can be used to remove the Hepatitis C virus and fragments thereof in hemodialysis patients, and to provide a sustained reduction in viral load.

Devices, systems and methods for reducing the concentration of a chemical entity in fluids

A method of improving the blood compatibility of a blood-contacting surface includes immobilizing carbonic anhydrase on the surface, wherein the surface exhibits carbonic anhydrase activity of at least 20% of maximum theoretical activity of the surface based on monolayer surface coverage of carbonic anhydrase.

Drug-adsorbing material and medical device comprising same

A drug-adsorbing material capable of efficiently adsorbing and eliminating drugs (such as carcinostatic agents) from blood with a small amount without causing foreign body recognition reaction, such as blood coagulation, and a medical device provided with said drug-adsorbing material. The drug-adsorbing material is based on polymeric microparticles which swell upon adsorption of plasma components at pH value of 7 or above and keep their shape after swelling. The drug-adsorbing material is incorporated into a drug-administrating device for drug adsorption.

Polymers for reversing heparin-based anticoagulation

Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.

Method and system to remove soluble tnfr1, tnfr2 and il2 in patients

A method, and system, to induce remission in diseases characterized by excess production of sTNR and interleukin 2 has been developed. In the most preferred embodiment, the system consists of antibodies to sTNFR1, sTNFR2 and sIL2R immobilized in a column containing a material such as SEPHAROSE™. The patient is connected to a pheresis machine which separates the blood into the plasma and red cells, and the plasma is circulated through the column until the desired reduction in levels of sTNFR1, sTNFR2, and IL2 is achieved, preferably to less than normal levels. In the preferred method, patients are treated three times a week for four weeks. This process can be repeated after a period of time. Clinical studies showed reduction in tumor burden in patients having failed conventional chemotherapy and radiation treatments.

SUBSTRATE FOR LIGAND IMMOBILIZATION AND METHOD FOR PRODUCING SAME

The present invention provides a substrate for ligand support in which a copolymer represented by the following formula (1) is bonded to at least a surface of a water-insoluble carrier: 3. The substrate for ligand support according to claim 1 , wherein the copolymer has an epoxy group.4. The substrate for ligand support according to claim 1 , wherein a coverage of the water-insoluble carrier surface with the copolymer is greater than or equal to 27%.5. The substrate for ligand support according to claim 1 , wherein the water-insoluble carrier is a porous membrane or particles.7. The use of a copolymer according to claim 6 , wherein the copolymer has an epoxy group.9. The method for producing a substrate for ligand support according to claim 8 , wherein the polymerizable monomer has an epoxy group.10. The method for producing a substrate for ligand support according to claim 8 , wherein the water-insoluble carrier is a porous membrane or particles.11. An adsorbent in which a ligand selected from the group consisting of antibodies claim 1 , proteins claim 1 , peptides and low-molecular-weight compounds is bonded to the substrate for ligand support according to .12. A blood treatment equipment in which the inside of a container equipped with an inlet for introducing blood to the inside and an outlet for discharging the blood to the outside is filled with the adsorbent according to . The present invention relates to a substrate for ligand support for supporting affinity ligands and a method for producing the same.For the purpose of removing particular components from blood, adsorbents in which substances having affinity for the particular components, i.e., ligands, are supported on water-insoluble carriers by covalent bond are clinically widely used. These adsorbents are used in a form in which patient blood is temporarily taken out of the body and the blood or plasma separated with a plasma separator is treated by flowing in the adsorbent and then returned to the ...

Medium, devices and methods

A separation medium is provided, comprising at least one megalin polypeptide and/or at least one cubilin polypeptide immobilized on a support. Also provided are devices comprising the separation medium, as well as methods and uses employing the separation medium for extracorporeal removal of low molecular weight proteins, or fragments or derivatives thereof, from complex biological fluids.

Methods to detect and treat diseases

The current invention discloses methods to treat disease caused by virus infection, bacterial infection, parasites infection, autoimmune disease, disease caused by production of unwanted antibodies, sepsis as well as methods to treat cancer and methods for virus infection detection using blood purification method. The current invention provides a method to treat pathogen infection by inactivating the pathogens in the blood. During the treatment, blood is withdrawn from a patient and is separated into its plasma and cellular components. The plasma portion is treated with physical means such as UV radiation to inactivate the pathogens inside and then is returned to the patient. The current invention also provide a method to treat cancer especially to prevent tumor metastasis and tumor recurrence by removing and/or inactivating (e.g. killing) the circulating tumor cells (CTC) in the blood after removing the tumor or treating the tumor with therapeutical means.

Apparatus for Blood Purification by Extracorporeal Circulation

A blood purification device includes a loop for extracorporeal circulation of blood consisting of an element () that extracts plasma from the blood and elements for circulating the thus extracted plasma in elements for purifying the plasma ( or ). The device includes in addition a column () in the blood circulation loop. 1. Blood purification device that comprises a loop for extracorporeal circulation of blood that consists of an element that extracts plasma from the blood and means for circulation of the thus extracted plasma in plasma purification means , characterized in that it comprises in addition one column in said blood circulation loop.2. Device according to claim 1 , wherein the column retains leukocytes.3. Device according to claim 1 , wherein the column and the element are placed in series on the blood circulation loop.4. Device according to claim 1 , wherein the column and the element are placed in parallel on the blood circulation loop.5. Device according to claim 1 , wherein the plasma is thrown out into a tank and then fully or partially compensated by a substitution liquid contained in a tank.6. Device according to claim 1 , wherein the extracted plasma is circulated through a filter and then returned into the blood circulation loop.7. Device according to claim 1 , wherein the extracted plasma is circulated through a filter and an adsorbent cartridge and then returned into the blood circulation loop.8. Device according to claim 1 , wherein the extracted plasma is circulated through two adsorbent cartridges and then returned into the blood circulation loop.9. Device according to claim 1 , wherein the extracted plasma is circulated through a single adsorbent cartridge retaining antibodies and cytokines and then returned into the blood circulation loop. This invention relates to a device for purification of the blood of patients who exhibit a pathology that makes it necessary to reduce the circulating amounts of several substances having different ...

Catheter

In one aspect, the invention provides a device comprising a catheter. In another aspect, the invention provides a method of removing an agent from blood.

Recirculating fluid filtration system

A fluid filtration system comprising a cross-flow filter is arranged to permit a first pump to recirculate part of the retentate of the filter to the inlet of the cross-flow filter and a second pump to return part of the permeate to the inlet of the cross-flow filter. A third pump is configured supply source fluid to the inlet of the filter. The flow path between the second pump and the cross-flow filter inlet may include an adsorption filter that may selectively remove contaminants, toxins, or pathogens in the permeate. A controller may control the first, second and third pumps to provide predetermined flow ratios among the fluid flow paths of the system in order to achieve a desired filtration level. This system may be applicable to the removal of harmful substances from blood, by first separating the plasma from the blood and then removing harmful substances from the plasma.

ADSORBENT FOR THE REMOVAL OF BLOOD CELLS

A blood cells removal module including a casing having an inlet into which a blood flow before blood cells removal flows, and an outlet in which a blood flow after blood cells removal is discharged, an adsorbent for blood cells removal of short fiber shape accommodated in the casing, a mesh being provided inside the inlet and the outlet, respectively, and holding the adsorbent for blood cells removal in the casing, wherein a length of the adsorbent for blood cells removal is within a range from 1 to 60% of the internal diameter of the casing. 1. A blood cells removal module , comprising:a casing having an inlet into which a blood flow before blood cells removal flows, and an outlet in which a blood flow after blood cells removal is discharged,an adsorbent for blood cells removal of a short fiber shape is accommodated in the casing,a mesh being provided inside the inlet and the outlet, respectively, and holding the adsorbent for blood cells removal in the casing, whereina length of the adsorbent for blood cells removal is within a range from 1 to 60% of the internal diameter of the casing.2. The blood cells removal module according to claim 1 , wherein the length of the adsorbent for blood cells removal is within a range from 18 to 56% of the internal diameter of the casing.3. The blood cells removal module according to claim 1 , wherein a filling rate of the adsorbent for removing blood cells relative to the volume of the casing is within a range from 20 to 60%.4. The blood cells removal module according to claim 1 , wherein the adsorbent is in a form of hollow fibers or solid fibers.5. The blood cells removal module according to claim 1 , wherein the adsorbent for removing blood cells is formed from a hydrophobic polymer resin.9. The blood cells removal module according to claim 1 , wherein the adsorbent is used for removing white blood cells and platelets from blood. This is a Continuation of application Ser. No. 12/937,163, filed Oct. 8, 2010, which in turn is a ...

Urea Sorbent

A sorbent polymer is provided that interacts or reacts with aqueous urea to aid the regeneration of a dialysate liquid. The sorbent polymer may include one or more specific functional groups bonded thereto. Such specific functional groups are selected from carboxylic acids, carboxylic acid esters, carboxylates, amides, dicarboxylic acids, dicarboxylic acid esters, and dicer boxylates to produce the desired urea sorbent. 1. A filter for regenerating dialysate comprising:a sorbent layer comprising a polymer having specific functional groups bonded thereto that interact with urea at a pH of between 5 and 10 to remove urea from an aqueous solution, wherein the polymer is substantially insoluble in water and interacts with urea in a predetermined temperature range and without releasing ammonia and wherein the reaction product of the polymer and urea is substantially insoluble in water; andactivated carbon for absorbing organic metabolites from the dialysate.2. The filter of claim 1 , further comprising an anion exchange layer for removing anions from the dialysate.3. A dialysate regenerating filter for removing solids or liquids from dialysate comprising:a sorbent layer comprising a polymer having functional groups bonded thereto that interact or react with urea at a pH of between 4 to 12 and bind urea from an aqueous solution, wherein the polymer is either soluble or substantially insoluble in water and interacts or reacts with urea without releasing ammonia and wherein the interaction or reaction product of the polymer and urea is either soluble or substantially insoluble in water; andactivated carbon for absorbing organic metabolites from the dialysate.4. The filter of claim 3 , further comprising an anion exchange layer for removing anions from the dialysate.5. The filter of claim 3 , wherein the functional groups interact or react with urea at a pH of between 6 and 9.6. The filter of claim 3 , wherein the polymer is insoluble in water.7. The filter of claim 3 , ...

CARRIER FOR BLOOD COMPONENT ADSORPTION AND BLOOD COMPONENT ADSORPTION COLUMN

A carrier for blood component adsorption enables selective and efficient adsorption removal of granulocytes and monocytes and, at the same time, enables adsorption removal of inflammatory cytokines. The carrier for blood component adsorption includes a water-insoluble carrier having a surface to which a functional group(s) containing a silyl group and an amino group is/are introduced. 110.-. (canceled)11. A carrier for blood component adsorption comprising a water-insoluble carrier having a surface to which a functional group(s) containing a silyl group and an amino group is/are introduced.12. The carrier according to claim 11 , wherein said water-insoluble carrier has a proton adsorption capacity of 1.5×10to 3.0×10eq/g.13. The carrier according to claim 11 , wherein the silicon atom of said silyl group and the nitrogen atom of said amino group are linked together by an alkyl chain.14. The carrier according to claim 13 , wherein said alkyl chain is an alkyl chain having not more than 6 carbon atoms.15. The carrier according to claim 11 , wherein said silyl group has an alkyl group and/or alkoxy group.16. The carrier according to claim 15 , wherein said alkyl group is a methyl group or ethyl group.17. The carrier according to claim 15 , wherein said alkoxy group is a methoxy group or ethoxy group.18. The carrier according to claim 11 , wherein said water-insoluble carrier is composed of a fiber or particle.19. The carrier according to claim 18 , wherein said fiber has a fiber diameter of claim 18 , or said particle has a particle diameter of claim 18 , 0.5 to 20 μm.20. A column for blood component adsorption filled with the carrier for blood component adsorption according to .21. The carrier according to claim 12 , wherein the silicon atom of said silyl group and the nitrogen atom of said amino group are linked together by an alkyl chain.22. The carrier according to claim 12 , wherein said silyl group has an alkyl group and/or alkoxy group.23. The carrier according ...

MICROPOROUS ZIRCONIUM SILICATE AND ITS METHOD OF PRODUCTION

The present invention relates to novel microporous zirconium silicate compositions having a desired particle size distribution and methods of making those compositions. These compositions have an ideal particle size distribution for use ex vivo, for example in a dialysis exchange cartridge, yet retain many of the desirable properties of prior improved absorbers including high cation exchange capacity. Further, the new zirconium silicate molecular sieve absorbers can be manufactured using a technique that achieves the desired particle size distribution while eliminating the screening step that was previously necessary. 1. A cation exchange composition comprising a zirconium silicate of formula (I):{'br': None, 'sub': p', 'x', '1-x', 'n', 'y', 'm, 'AMZrSiGeO\u2003\u2003(I)'} A is a potassium ion, sodium ion, rubidium ion, cesium ion, calcium ion, magnesium ion, hydronium ion or mixtures thereof,', 'M is at least one framework metal, wherein the framework metal is hafnium (4+), tin (4+), niobium (5+), titanium (4+), cerium (4+), germanium (4+), praseodymium (4+), terbium (4+) or mixtures thereof,', '“p” has a value from about 1 to about 20,', '“x” has a value from 0 to less than 1,', '“n” has a value from about 0 to about 12,', '“y” has a value from 0 to about 12,', '“m” has a value from about 3 to about 36 and 1≦n+y≦12,', 'wherein the composition exhibits a volume weighted mean particle size between 5 and 20 microns wherein less than 10% of the particles have a size below 5 microns and less than 10% of the particles have a size above 25 microns, wherein the particle size distribution does not result from a screening or classification process., 'where'}2. The cation exchange composition of claim 1 , wherein the mean particle size is between 10 and 15 microns.3. An ion exchange column loaded with exchange media claim 1 , wherein the exchange media comprises the cation exchange composition of .4. The composition of claim 1 , wherein the potassium exchange capacity is ...

THERAPEUTIC RETRIEVAL OF TARGETS IN BIOLOGICAL FLUIDS

Method and apparatus for removing high density particles from a biological fluid such as blood using aphaeresis. The particles are preferably sub-micron in size and denser than normally occurring components of the fluid and can be removed by a modified reverse-flow gradient density centrifuge without damaging the fluid. The particles can be provided to a patient in vivo or added to the fluid after it is removed from the patient. Some particles can carry and deliver oxygen and scavenge carbon dioxide. Other particles are conjugated to capture molecules for attaching to targets such as cancer cells, viruses, pathogens, toxins, or excess concentrations of a drug or element in the fluid. The targets are then removed from the fluid along with the particles by the aphaeresis instrument. 1. A method for introducing and removing high density particles from a biological fluid , the method comprising:introducing high density particles into a biological fluid, the high density particles comprising a density greater than any naturally occurring component of the biological fluid; andremoving at least some of the high density particles from the biological fluid using aphaeresis.2. The method of wherein the introducing step is performed in vivo.3. The method of wherein the introducing step is performed extracorporeally.4. The method of further comprising transferring the biological fluid from a patient prior to the introducing step.5. The method of wherein the particles deliver oxygen in the biological fluid and scavenge carbon dioxide from the biological fluid.6. The method of further comprising conjugating the particles to one or more capture molecules.7. The method of further comprising attaching at least some of the particles to one or more targets in the biological fluid via the capture molecules prior to the removing step.8. The method of wherein the removing step comprises removing at least some of the attached targets from the biological fluid.9. The method of wherein the ...

Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines

The present invention is directed to an integrated system and a method for utilizing the system to detect and remove blood-borne factors of interest, such as pathogens and/or toxins and/or cytokines, from blood or serum (blood) by contacting the blood with a solid, essentially nonporous substrate which has been surface treated with molecules or chemical groups (the adsorbent media or media) having a binding affinity for the pathogens and/or toxins to be removed (the adsorbents). The invention can be used to remove virulence factors, e.g. toxins, that are released from various pathogens. In one aspect, the invention is for the treatment of sepsis and infection, such as infections associated with battle field trauma.

Method And Apparatus For Producing Autologous Clotting Components

A method and apparatus for obtaining various components of a multi-component material. Generally, a component of a whole blood sample may be concentrated from a patient and re-introduced to the same patient. For example, a clotting component, such as thrombin, from a whole blood sample may be extracted and concentrated in an apparatus and collection to be reapplied or reintroduced into a patient. 1. A kit for forming a selected component from a whole blood sample , comprising: a container operable to contain the multi-component material;', 'an activating member and/or a desiccating member positioned in said container and operable to contact the multi-component material;', 'a mixing assembly operable to mix the multi-component material and said activating member and/or said desiccating member;, 'a first whole blood separation apparatus comprising a container operable to contain a volume of whole blood;', 'a first piston operable to move through the volume of the whole blood;', 'a second piston operable to move through the whole blood and defining a platelet collection area;', 'a withdrawal member operable to interconnection said platelet collection area and an outlet port;', 'wherein said first whole blood separation device and said second whole blood separation device are operable to separate and/or concentrate selected and different components of the whole blood sample., 'a second whole blood separation apparatus comprising2. The kit of further comprising:a container including a selected volume of ethanol;wherein said container is operable to provide to said first whole blood separation apparatus a volume of ethanol to achieve about 4 percent to about 7 percent ethanol when added to the mixture of the whole blood sample.3. The kit of claim 1 , further comprising:a volume of calcium chloride operable to allow a selected volume of the volume of calcium chloride to be introduced into the first whole blood separation apparatus;wherein the selected volume of the calcium ...

COMPOSITIONS AND METHODS USEFUL IN SELECTIVELY MODIFYING THE INTERNAL AND EXTERNAL SURFACES OF POROUS POLYMER BEADS

The invention concerns polymer systems comprising at least one polymer with a plurality of pores where the polymer is initially functionalized on substantially all surfaces followed by a stepwise surface specific functionalization such that a different functional group resides on the external or internal pore surface of the bead. The invention also concerns use of such polymer systems in blood, blood product, or physiologic fluid purification. 1. A polymer system comprising at least one polymer , said polymer comprising residues of one or more aromatic monomers and one or more cross-linking agents , said polymer having an external surface and a plurality of pores , said polymer being functionalized with different functional groups on said external surface and on surfaces within said pores; wherein at least one of said functional groups is selected from aldehyde , carboxylic acid , ether , ester , aromatic , alkyl aromatics , alkyl , wherein said aromatic alkyl aromatic , and alkyl groups may optionally be substituted with aldehyde , carboxylic acid , alkyl , aromatic , halogen , ester or ether.2. The polymer system of claim 1 , wherein said aromatic monomers comprise at least one of styrene and ethylvinylbenzene.3. The polymer system of claim 1 , wherein said aromatic monomers comprise styrene and ethylvinylbenzene.4. The polymer system of claim 1 , wherein said crosslinking agent comprise at least one of divinylbenzene claim 1 , trivinylcyclohexane claim 1 , trivinylbenzene claim 1 , divinylnaphthalene claim 1 , divinylsulfone claim 1 , trimethylolpropane triacrylate claim 1 , and trimethylolpropane trimethacrylate.5. The polymer system of claim 1 , wherein said aromatic monomers comprise styrene and ethylvinylbenzene and said crosslinking agent comprise at least one of divinylbenzene claim 1 , trivinylcyclohexane claim 1 , trivinylbenzene claim 1 , divinylnaphthalene claim 1 , divinylsulfone claim 1 , trimethylolpropane triacrylate claim 1 , and trimethylolpropane ...

AB-REMOVER, AB-REMOVING APPARATUS, AND AB REMOVAL METHOD

An object is to provide a material capable of removing Aβ from a body fluid efficiently and use of the material, which are developed for the purpose of establishing a therapeutic or preventive method for Alzheimer's disease. Provided is an amyloid β protein remover, containing a carrier made of any one material selected from the group consisting of cellulose, silica, polyvinyl alcohol, and activated carbon, wherein the carrier does not have an alkyl chain on the surface thereof or has an alkyl chain having 1 to 18 carbon atoms on the surface thereof. 1. A method of removing amyloid β protein , comprising:identifying a patient in need of removal of amyloid β protein; andcontacting a body fluid of said patient with a composition including a carrier made of any one material selected from the group consisting of cellulose, silica, polyvinyl alcohol, and activated carbon,wherein the carrier does not have an alkyl chain on the surface thereof or has (i) a hydrophilic polymer, (ii) tryptophan or (iii) an alkyl chain having 1 to 22 carbon atoms on the surface thereof.2. The method according to claim 1 , wherein the carrier is made of cellulose or activated carbon.3. The method according to claim 1 , wherein the carrier is made of silica and the alkyl chain is bound to the carrier via a silanol group (SiOH).4. The method according to claim 3 , wherein the number of carbon atoms is 1 to 5.5. The method according to claim 3 , wherein the number of carbon atoms is 1 to 2.6. The method according to claim 1 , wherein the carrier is made of silica and the carrier does not have an alkyl chain on the surface thereof.7. The method according to claim 1 , wherein the carrier is made of activated carbon and the surface of the carrier is covered with a hydrophilic polymer.8. The method according to claim 7 , wherein the hydrophilic polymer is a polymer of methacrylic acid 2-hydroxyethyl ester (pHEMA). This application is a continuation of U.S. application Ser. No. 13/166,431 filed Jun. ...

Apparatus, system, and method for creating biologically protected/enhanced spaces in vivo

The present invention creates a biologically protected or enhanced space in vivo in a mammal to allow the mammal's immune system and/or other biological processes to function properly in order to treat autoimmune diseases. In particular, the biologically protected/enhanced space allows biological processes to occur that can therapeutically treat Type I diabetes. The biologically enhanced/protected space can also be used to promote growth of specific cells such as insulin producing islet cells of the pancreas. Microfluidic devices can also be used to remove soluble TNF receptors and autoreactive T Cells in treating autoimmune diseases. Additionally, microfluidic devices can be used to remove blood glucose, soluble insulin receptors and insulin-like growth factor (IGF) from blood in the treatment of adult onset (Type II) diabetes.

Reduction of galectin-3 levels by plasmapheresis

The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.

TOXIN SEPARATOR

Provided are a toxin separator and the like which are capable of selectively separating toxin present in a biological fluid by binding to protein, from the toxin and the protein. The toxin separator of the present invention also includes activated carbon of which a pore volume of pores having a pore diameter from 1.4 to 35 nm as measured by a nitrogen adsorption method is 0.06 cm/g or greater. 1. A toxin separator that separates toxin from a biological fluid ,wherein the toxin is bound to protein to be present in the biological fluid,{'sup': '3', 'the toxin separator includes activated carbon having a pore volume of pores having a pore diameter from 1.4 to 35 nm, as measured by a nitrogen adsorption method, of 0.06 cm/g or greater, and'}{'sup': '2', 'the activated carbon has a pore surface area of 0.10 m/g or greater of pores having a pore diameter from 50 to 10000 nm as measured by a mercury intrusion porosimetry.'}2. The toxin separator according to claim 1 , wherein the toxin is a uremic toxin.3. (canceled)4. The toxin separator according to claim 1 , wherein the activated carbon is spherical.5. The toxin separator according to claim 1 , wherein the biological fluid is blood.6. The toxin separator according to claim 1 , which is a blood purification column.7. A blood purification system comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the toxin separator described in ; and'}a dialyzer.8. A toxin separation method of separating toxin from a biological fluid claim 1 ,wherein the toxin is bound to protein to be present in the biological fluid, and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the method includes passing the biological fluid through the toxin separator described in .'}9. (canceled) The present invention relates to a toxin separator that separates toxin from a biological fluid.In order to remove toxins contained in blood of a patient with renal disease, a method has been performed to form a blood circulation path outside the body of ...

METHOD FOR TREATING DRUG INTOXICATION

Methods and devices are disclosed for the treatment of a subject suffering from drug intoxication by cleansing a contaminated sample from the subject with adsorption media. The adsorption media composition is selected for its antithrombogenic properties and for its ability to adhere to one or more drug targets to be reduced or eliminated. The media can further be held in a cartridge for use in extracorporeal treatments such as those of hemoperfusion. Contacting the contaminated sample from the subject with the absorption medium allows for the separation of a portion of the drug target from the sample, producing a cleansed sample that can be infused into the subject. 1. A method for treating drug intoxication or removing a toxin in a subject in need thereof , said method comprising:contacting a sample from a subject suffering from drug intoxication or other intoxication with an adsorption media comprising a combination of activated carbon and a substrate having at least one polysaccharide adsorbent to form a cleansed sample; andinfusing the cleansed sample into the subject.2. The method of claim 1 , wherein the adsorption media and the drug form an adhering complex.3. The method of claim 2 , further comprising separating the resulting sample from the adhering complex to produce a cleansed sample with a reduced amount of drug.4. The method of claim 1 , wherein the drug is a member selected from the group consisting of analgesics claim 1 , sedatives claim 1 , hypnotics claim 1 , antipsychotics claim 1 , antidepressants cardiovascular drugs claim 1 , antihistamines claim 1 , topical preparations claim 1 , cold and cough preparations claim 1 , stimulants claim 1 , street drugs claim 1 , recreational drugs claim 1 , antibiotics claim 1 , antimicrobials claim 1 , hormones claim 1 , hormone antagonists claim 1 , anticonvulsants claim 1 , gastrointestinal preparations claim 1 , dietary supplements claim 1 , and herbals.5. The method of claim 4 , wherein the drug is an ...

BLOOD PURIFICATION DEVICE AND METHOD FOR PRODUCING SAME

A blood purification device includes a porous molded body containing an inorganic ion-adsorbing material and is characterized by the following: the concentrations of Mg, Al, Ti, V, Cr, Mn, Fe, Ni, Cu, Zn, Ga, Rb, Sr, Y, Zr, Mo, Ru, Ag, Cd, Sn, Cs, La, Pr, Sm, Gd, Tb, Ta, Au, Tl, Co, In, and Bi are each 0.1 ppb or less and the concentrations of Ba, Nd, Pb, And Ce are each 1 ppb or less in a physiological saline solution for injection both three months and six months after said physiological saline solution for injection is sealed in the blood purification device; and the number of fine particles having a size of 10 μm or more is 25 or less and the number of fine particles having a size of 25 μm or more is 3 or less in 1 mL of the physiological saline solution for injection. 1. A blood purification device comprising a porous molded body that includes an inorganic ion adsorbent , wherein the concentrations of Mg , Al , Ti , V , Cr , Mn , Fe , Ni , Cu , Zn , Ga , Rb , Sr , Y , Zr , Mo , Ru , Ag , Cd , Sn , Cs , La , Pr , Sm , Gd , Tb , Ta , Au , Tl , Co , In and Bi are all 0.1 ppb or lower and the concentrations of Ba , Nd , Pb and Ce are all 1 ppb or lower , in physiological saline for injection in the blood purification device at 3 months and 6 months after opening the physiological saline for injection , while the number of microparticles with sizes of 10 μm or greater is no more than 25 and the number of microparticles with sizes of 25 μm or greater is no more than 3 , in 1 mL of the physiological saline for injection at 3 months and 6 months after the same physiological saline for injection has been encapsulated in the blood purification device.2. The blood purification device according to claim 1 , wherein the porous molded body is composed of a porous molded body-forming polymer claim 1 , a hydrophilic polymer and an inorganic ion adsorbent.3. The blood purification device according to claim 2 , wherein the porous molded body-forming polymer is an aromatic ...

Process for removing mercury ions from bodily fluids using titanium metallate ion exchange compositions

A process for removing Hg 2+ toxins from bodily fluids is disclosed. The process involves contacting the bodily fluid with a titanium metallate ion exchanger to remove the metal toxins in the bodily fluid, including blood and gastrointestinal fluid. Alternatively, blood can be contacted with a dialysis solution which is then contacted with the ion exchanger. The titanium metallate ion exchangers are represented by the following empirical formula: A m TiNb a Si x O y . A composition is provided with the combination of the titanium metallate ion exchanger and bodily fluids or dialysis solutions. Also, provided is an apparatus comprising a matrix and the titanium metallate ion exchanger.

Use Of A Hemocompatible Porous Polymer Bead Sorbent For Removal Of Endotoxemia-Inducing Molecules

The invention concerns biocompatible polymer systems comprising at least one polymer with a plurality of pores, said polymer comprising either polyol or zwitterionic groups designed to adsorb endotoxins and other inflammatory mediator molecules. The inventions are in the field of porous polymeric sorbents, also in the field of broadly reducing endotoxins in blood and blood products that can cause endotoxemia, additionally, in the field of broadly removing endotoxins by perfusion or hemoperfusion. 140-. (canceled)41. A method of adsorbing toxins and inflammatory mediators comprising contacting physiologic fluid with a polymer system comprising either polyol or zwitterionic functionality;said polymer system has the form of a solid support having a polymer coating comprising poly(diethylaminoethyl methacrylate), poly(dimethylaminoethyl methacrylate), poly(hydroxyethyl acrylate), poly(hydroxyethyl methacrylate), poly(hydroxypropyl acrylate), poly (hydroxypropyl methacrylate), poly(N-vinylpyrrolidone), poly(vinyl alcohol), salts of poly(acrylic acid), salts of poly(methacrylic) acid, or mixtures thereof.42. The method of wherein the said toxins and inflammatory mediators have a molecular weight of from less than 0.5 kDa to 1 claim 41 ,000 kDa.43. The method of wherein the said toxins and inflammatory mediators have a molecular weight of from less than 0.5 kDa to 60 kDa.44. The method of wherein the toxins and inflammatory mediators comprise one or more of cytokines claim 41 , pathogen-associated molecular pattern molecules (PAMPs) claim 41 , damage-associated molecular pattern molecules (DAMPs) claim 41 , superantigens claim 41 , monokines claim 41 , chemokines claim 41 , interferons claim 41 , proteases claim 41 , enzymes claim 41 , peptides including bradykinin claim 41 , soluble CD40 ligand claim 41 , bioactive lipids claim 41 , oxidized lipids claim 41 , cell-free hemoglobin claim 41 , cell-free myoglobin claim 41 , growth factors claim 41 , glycoproteins claim 41 , ...

BLOOD FILTER

A blood filter device having an iron-chelating molecule, a haem-binding molecule and a haemoglobin-binding molecule bound to a support. Use of the device in a vessel containing blood, for example a blood bag or a flow line, removes haemolysis-derived components from the blood. 1. A device for removal of haemolysis-derived components from blood , the device comprising:a support,a plurality of binding agents bound to said supportwherein the binding agents comprise at least one iron-chelating molecule, at least one haemoglobin-binding molecule, and at least one haem-binding molecule.2. A device according to further comprising a vessel for the storage or passage of blood claim 1 , wherein the vessel contains the support.3. A device according to claim 1 , wherein the support is a plurality of beads.4. A device according to claim 1 , wherein each bead of the plurality of beads is bound to no more than one of: the iron-chelating molecule claim 1 , the haemoglobin-binding molecule claim 1 , and the haem-binding molecule.5. A device according to claim 1 , wherein the support is a single element to which at least one iron-chelating molecule claim 1 , at least one haemoglobin-binding molecule claim 1 , and at least one haem-binding molecule are bound claim 1 , preferably wherein all of the plurality of binding agents are bound to the single element.6. A device according to claim 1 , wherein the support is wholly or partially integrated with the vessel.7. A device according to wherein the support is not integrated with the vessel.8. A device according to claim 1 , wherein the support comprises an insoluble polymer or a glass claim 1 , or preferably wherein the insoluble polymer is a natural functionalised biopolymer claim 1 , preferably a polysaccharide polymer claim 1 , preferably agarose claim 1 , or further preferably wherein the insoluble polymer is a synthetic polymer claim 1 , preferably a synthetic co-polymer claim 1 , preferably a PEGylated synthetic polymer.910.-. ( ...

SYSTEM FOR REMOVING UREMIC TOXINS IN DIALYSIS PROCESSES

A dialysis system comprising: a sorbent cartridge including a zirconium phosphate layer followed by at least one of a urease layer, a zirconium oxide layer, or a carbon layer; a pump in fluid communication sorbent cartridge; and a control unit in operable communication with the pump, wherein the control unit is programmed to cause the pump to pump a dialysis fluid to flow (i) in a first direction through the sorbent cartridge, wherein the zirconium phosphate layer is contacted by the dialysis fluid before the at least one of the urease layer, zirconium oxide layer or carbon layer and (ii) in a second direction through the sorbent cartridge wherein the at least one of the urease layer, zirconium oxide layer or carbon layer is contacted by the dialysis fluid before the zirconium phosphate layer. 1. A dialysis system comprising:a sorbent cartridge in fluid communication with at least one of a patient or a dialyzer, the sorbent cartridge including a housing having a urease layer followed by a zirconium phosphate layer;a storage container in fluid communication with the sorbent cartridge;a pump in fluid communication with the sorbent cartridge and the storage container; anda control unit in operable communication with the pump, wherein the control unit is programmed to cause the pump to pump a dialysis fluid to flow (i) in a first direction through the sorbent cartridge, wherein the urease layer is contacted by the dialysis fluid before the zirconium phosphate layer and (ii) in a second direction, reverse from the first direction, through the sorbent cartridge wherein the zirconium phosphate layer is contacted by the dialysis fluid before the urease layer.2. The dialysis system of claim 1 , wherein the control unit is programmed to cause the pump to recirculate the dialysis fluid through the sorbent cartridge for at least two cycles claim 1 , after which the dialysis fluid is stored in the storage container.3. The dialysis system of claim 2 , wherein the control unit is ...

SINGLE PASS DIALYSIS COMBINED WITH MULTIPLE PASS ALBUMIN DIALYSIS

Methods, systems, and devices are disclosed, embodiments of which provide single pass dialysis to remove water and uremic toxins is performed simultaneously with the albumin dialysis therapy by passing the albumin solution through a dialysis filter which dialyses it before the solution is returned to the cycler. In embodiments, the single pass dialysis stage is upstream of the albumin filtering stage. 1. A device for adapting a blood treatment cycler for the simultaneous clearance of albumin-bound molecules and solutes from blood , comprising:a medical treatment cycler configured to balance ingoing and outgoing flows of a medical treatment fluid and adapted to provide a selectable difference between ingoing and outgoing flows, the medical treatment cycler being configured to receive and interoperate with a predefined disposable tubing set with a first filter and fluid inlet and outlet connectors for a balanced medical treatment fluid;a supplemental fluid management system having a second filter and connectable to the inlet and outlet connectors;the supplemental fluid management system being configured to clear solutes from a solution received at the outlet connector and to supply solute-cleared fluid to the inlet connector;the supplemental fluid management system being configured to adapt automatically to the medical treatment cycler selecting, and altering in real time, a rate of fluid flow to and from, respectively, the outlet and inlet connectors, thereby providing automatic interoperability with the medical treatment cycler.2. The device of claim 1 , wherein the medical treatment cycler is adapted for performing at least one of dialysis claim 1 , hemofiltration claim 1 , and hemodiafiltration.3. (canceled)4. The device of claim 1 , wherein the medical treatment cycler is configured to generate a flow rate from the outlet port that is higher than a flow rate to the inlet port claim 1 , the difference being selectable by a user claim 1 , and the supplemental fluid ...

METHOD FOR EXTRACORPOREAL REMOVAL OF PATHOGENIC MICROBE, AN INFLAMMATORY CELL OR AN INFLAMMATORY PROTEIN FROM BLOOD

The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein. 1. A method for treating a subject in need thereof , by extracorporeal removal of a pathogenic microbe , an inflammatory cell or an inflammatory protein , said method comprising:a) contacting said subject's whole blood with heparin immobilized on a solid substrate, wherein said heparin is covalently linked by end-point attachment under conditions allowing binding of said pathogenic microbe, said inflammatory cell or said inflammatory protein to the heparin;b) separating the whole blood from the solid substrate; andc) recovering said whole blood containing a reduced amount of said pathogenic microbe, said inflammatory cell or said inflammatory protein.2. The method of claim 1 , further comprising: d) reintroducing into said subject said whole blood containing a reduced amount of said pathogenic microbe claim 1 , said inflammatory cell or said inflammatory protein.3. The method of claim 1 , wherein said solid substrate comprises microparticles.4. The method of claim 1 , wherein said solid substrate ...

UREA SEQUESTRATION COMPOSITIONS AND METHODS

Graphene-based materials for sequestering urea from aqueous solutions are provided. The graphene-based materials include graphene aggregates as well as graphene oxides. 1. A method comprising:contacting a fluid comprising urea with a mass of graphene-based material particles;sorbing at least a portion of the urea into or onto the graphene-based material particles to produce a graphene-based material/urea complex; andreducing the level of urea in the fluid wherein the amount of urea in the graphene-based material/urea complex is greater than 25 mg urea per gram of graphene-based material.2. The method of wherein the fluid is selected from at least one of an aqueous fluid claim 1 , water claim 1 , whole blood claim 1 , blood plasma claim 1 , processed blood claim 1 , preserved blood claim 1 , serum claim 1 , plasma claim 1 , clotted blood claim 1 , anti-clotted blood claim 1 , centrifuged blood claim 1 , hematocrit claim 1 , biological filtrate claim 1 , ultrafiltrate claim 1 , dialysate claim 1 , extracellular fluids claim 1 , intracellular fluids claim 1 , interstitial fluids claim 1 , lymphatic fluids claim 1 , transcellular fluids claim 1 , urine claim 1 , urine-derived fluids claim 1 , agricultural runoff and sewage.3. (canceled)4. The method of wherein the concentration of urea in the fluid is reduced by greater than 10 percent by weight.5. The method of comprising agitating claim 1 , stirring claim 1 , shaking claim 1 , sonicating claim 1 , flowing claim 1 , cooling and/or heating a suspension of the graphene-based material particles in the fluid.6. The method of claim 1 , the method comprising flowing the fluid through a bed comprising graphene-based material particles.7. The method of wherein the graphene-based material is graphene oxide having an atomic ratio of carbon to oxygen of from 20:1 to 1.5:1.8. The method of wherein the graphene-based material is a graphene aggregate.9. The method of comprising removing at least one non-urea component of the fluid ...

Biocompatible nanomagnetic discs and methods of use thereof

Provided herein are compositions including biocompatible magnetizeable nanoparticles. The nanoparticles have a diameter (average diameter) from about 10 to about 300 nanometers and are biocompatible and magnetic. The nanoparticles may be a disc formed from iron oxide. The disc may be conjugated to a target-binding moiety capable of binding a target. The target may be cancer cells, pathogens, fat cells, or atherosclerotic plaques.

Device and Method for Attenuation of CO2 in Circulating Blood

Systems and methods for the removal of carbon dioxide from circulating blood via the use of microbubbles within a body cavity, optionally including the simultaneous provision of oxygen to the circulatory system. Through placement of microbubbles within a body cavity and the use of a carbon dioxide scavenging catheter, carbon dioxide and/or oxygen exchange may occur. Overall improvement in extending survival rate time during emergency situations caused by pulmonary or similar ventilation restricting injury and/or failure may be achieved. 1. A method of removing a gas from a circulatory system of a subject , comprising the steps of:delivering a plurality of microbubbles containing a first gas into an existing gastrointestinal body cavity of the subject, the first gas having a first percentage by volume;inserting a gas collecting device into the first plurality of microbubbles located within the gastrointestinal body cavity, the gas collecting device comprising a gas permeable outer layer and a material capable of absorbing the selected gas;wherein a gas located within the circulatory system of the subject diffuses through a tissue wall of the gastrointestinal body, through the plurality of microbubbles and through the gas permeable outer layer and is absorbed by the gas absorbing material.2. The method of claim 1 , where the gas collecting device contains a gas absorbing material selected from one of the members of a group consisting of chitosan; soda lime; calcium hydroxide lime; calcium hydroxide; sodium hydroxide; sodium hydroxide-coated silica; potassium hydroxide; lithium hydroxide; cuprous chloride; amine based solvents claim 1 , methylamine claim 1 , triethanolamine claim 1 , hexamethylenetetramine claim 1 , cyclohexylamine claim 1 , pyridine claim 1 , diphenylamine claim 1 , ethylenediamine claim 1 , ethylpiperidine claim 1 , benzimdazole claim 1 , triazine claim 1 , triphenylphosphine claim 1 , dimethylphosphine and any combinations thereof.3. The method of ...

Device for the selective removal of molecules from tissues or fluids

An implantable device is for the selective removal of molecules from tissues or fluids so as to allow the selective removal of a particular molecule of interest (target molecule) from any type of fluid solution or tissue, including biological tissues or fluids. The device operates through the complementary action of specific-binding molecules (antibodies) directed against the target molecule inside the device. The device includes a nanoperforated membrane having pores larger than the target molecule but smaller than the antibodies, such that the fluid can be removed through a second catheter with a lower concentration of target molecules.

Combined Bio-Artificial Liver Support System

A combined bio-artificial liver support system, includes branch tubes that are connected in sequence: a blood input branch tube, an upstream tail end, a first plasma separation branch tube comprising at least a first plasma separator, a non-biological purification branch tube comprising at least a plasma perfusion device and a bilirubin adsorber, a biological purification branch tube comprising at least a hepatocyte culture cartridge assembly, and a plasma return branch tube, a downstream tail end of which is set as a blood output end. 1. A combined bio-artificial liver support system , comprising a plurality of branch tubes that are connected in sequence: a blood input branch tube , an upstream tail end of which is set as a blood input end , a first plasma separation branch tube comprising at least a first plasma separator , a non-biological purification branch tube comprising at least a plasma perfusion device and a bilirubin adsorber , a biological purification branch tube comprising at least a hepatocyte culture cartridge assembly , and a plasma return branch tube , a downstream tail end of which is set as a blood output end , wherein by means of a three-way device , the first plasma separation branch tube is connected to inlet ends of the biological purification branch tube and the non-biological purification branch tube , an outlet end of the non-biological purification branch tube is connected to the biological purification branch tube , and the outlet end of the non-biological purification branch tube is connected to the plasma return branch tube , the three-way device comprises a three-way joint and branches respectively connected to the three-way joint , and at least two said branches are respectively provided with a flow restricting member and a coupling member.2. The combined bio-artificial liver support system as recited in claim 1 , wherein the first plasma separation branch tube comprises: a first plasma separator provided with a blood inlet claim 1 , ...

METHOD FOR REMOVING BACTERIA FROM BLOOD USING HIGH FLOW RATE

The present invention provides methods for removing a significant amount of bacteria (e.g., gram-negative bacteria and gram-positive bacteria, including bacteria with no or low affinity for heparan sulfate) from whole blood, serum or plasma using an adsorption media. The method can be used in extracorporeal treatments involving high volumetric flow rates and high linear flow rates. 1. An ex vivo method for removing bacteria from a sample taken from a subject who is suspected of being infected with bacteria , the method comprising:contacting a sample taken from the subject with an adsorption media to allow the formation of an adhering complex, wherein the adhering complex comprises bacteria and the adsorption media; andseparating the sample from the adhering complex to produce the sample with a reduced amount of bacteria.2. The method of claim 1 , wherein the sample is selected from the group consisting of whole blood claim 1 , serum and plasma.3. The method of claim 2 , wherein the sample is whole blood.4. The method of claim 1 , wherein the adsorption media is a solid substrate of high surface area having a hydrophilic surface that is free of a polysaccharide adsorbent.5. The method of claim 4 , wherein the solid substrate comprises a plurality of rigid polymer bead.6. The method of claim 5 , wherein the rigid polymer bead is a member selected from the group consisting of polyurethane claim 5 , polymethylmethacrylate claim 5 , polyethylene or co-polymers of ethylene and other monomers claim 5 , polyethylene imine claim 5 , polypropylene claim 5 , and polyisobutylene.7. The method of claim 4 , wherein the solid substrate comprises one or a plurality of hollow fibers.8. The method of claim 4 , wherein the solid substrate comprises solid fibers or woven yarn made from solid fibers.9. The method of claim 4 , wherein the hydrophilic surface is a cationic surface.10. The method of claim 1 , wherein the adsorption media has a high surface area as a result of surface or ...

TREATING MULTIPLE SCLEROSIS

A method for treating multiple sclerosis comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor CCR2, CCR6, CCR3, CCR5, CCR1, CXCR3 and/or CCR9 immobilized directly or indirectly on the support thus removing one or more chemokine receptor, optionally CCR2, CCR6, CCR3, CCR5, CCR1, CXCR3 and/or CCR9 expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described. 1. A method for treating multiple sclerosis in a subject in need thereof comprising applying peripheral blood from the subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor selected from chemokine receptor CCR2 , CCR6 , CCR3 , CCR5 , CCR1 , CXCR3 and CCR9 immobilized directly or indirectly on the support , whereby one or more cells expressing chemokine receptors CCR2 , CCR6 , CCR3 , CCR5 , CCR1 , CXCR3 and/or CCR9 are removed from the peripheral blood of the subject and the multiple sclerosis is treated.2. The method of claim 1 , wherein the multiple sclerosis is selected from active and stable relapsing-remitting multiple sclerosis claim 1 , primary progressive relapsing multiple sclerosis claim 1 , secondary progressive relapsing multiple sclerosis claim 1 , and progressive relapsing multiple sclerosis.3. The method of claim 1 , wherein the binding reagent is an agonist or an antagonist of CCR2 claim 1 , CCR6 claim 1 , CCR3 claim 1 , CCR5 claim 1 , CCR1 claim 1 , CXCR3 and/or CCR9.4. The method of claim 1 , wherein the binding reagent is an antibody or a chemokine.5. The method of claim 4 , wherein the chemokine is selected from MCP-1 claim 4 , MCP-2 claim 4 , MCP-3 claim 4 , MCP-4 claim 4 , MCP-5 claim 4 , MIP-3alpha claim 4 , MIG ( ...

TREATING RESPIRATORY CONDITIONS

A method for treating a respiratory conditions comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor CCR2, CCR1, CCR3, CCR5, CXCR1, CXCR2 and/or CCR7 immobilized directly or indirectly on the support thus removing one or more chemokine receptor, optionally CCR2, CCR1, CCR3, CCR5, CXCR1, CXCR2 and/or CCR7 expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described. 1. A method for treating a respiratory condition in a subject in need thereof , which comprises applying peripheral blood from the subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor selected from CCR2 , CCR1 , CCR3 , CCR5 , CXCR1 , CXCR2 and CCR7 immobilized directly or indirectly on the support , whereby one or more cells expressing chemokine receptors CCR2 , CCR1 , CCR3 , CCR5 , CXCR1 , CXCR2 and/or CCR7 are removed from the peripheral blood of the subject and the respiratory condition is treated.2. The method of claim 1 , wherein the respiratory condition is sarcoidosis or Chronic Obstructive Pulmonary Disease (COPD).3. The method of wherein the binding reagent is an agonist or an antagonist of CCR2 claim 1 , CCR1 claim 1 , CCR3 claim 1 , CCR5 claim 1 , CXCR1 claim 1 , CXCR2 and/or CCR7 claim 1 , respectively.4. The method of claim 1 , wherein the binding reagent is an antibody or a chemokine.5. The method of claim 4 , wherein:(a) the chemokine is selected from CCL2 (MCP-1), MCP-2, MCP-3, MCP-4 (CCL12), MCP-5, CCL5 (RANTES), CCL5, MRP-2 (CCL10), CCL14, CCL15, CCL16, CCL23, CCL11 (Eotaxin), CCL28, CCL24 (Eotaxin 2), CCL26, CCL3, CCL4, CCL5, CCL8, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8,(b) the chemokine is ...

TREATING CONDITIONS ASSOCIATED WITH SEPSIS

A method for treating sepsis and/or respiratory distress syndrome (RDS) comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor CCR5, CXCR1, CXCR2, and/or CCR2 immobilized directly or indirectly on the support thus removing one or more chemokine receptor, optionally CCR5, CXCR1, CXCR2, and/or CCR2 expressing cells from the peripheral blood of the patient or subject. Various companion therapeutic methods and useful binding reagents are also described. 1. A method for treating sepsis and/or respiratory distress syndrome (RDS) in a subject in need thereof , which comprises applying peripheral blood from the subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor selected from CCR5 , CXCR1 , CXCR2 , and CCR2 immobilized directly or indirectly on the support , whereby one or more cells expressing chemokine receptors CCR5 , CXCR1 , CXCR2 , and/or CCR2 are removed from the peripheral blood of the subject and the sepsis and/or respiratory distress syndrome (RDS) is treated.2. The method of claim 1 , wherein the sepsis is a systemic inflammation syndrome or causes multiple organ dysfunction syndrome claim 1 , or wherein the RDS is Acute RDS or sepsis-associated RDS.3. The method of claim 1 , wherein the binding reagent is an agonist or an antagonist of CCR2 claim 1 , CXCR1 claim 1 , CXCR2 and/or CCR5.4. The method of claim 1 , wherein the binding reagent is an antibody or a chemokine.5. The method of claim 4 , wherein the chemokine is selected from MCP-1 claim 4 , MCP-2 claim 4 , MCP-3 claim 4 , MCP-4 claim 4 , MCP 5 claim 4 , CXCL1 claim 4 , CXCL2 claim 4 , CXCL3 claim 4 , CXCL5 claim 4 , CXCL6 claim 4 , CXCL7 claim 4 , CXCL8 claim 4 , CCL5 claim 4 , CCL3 claim 4 , and CCL8.6. The method of ...

TREATING CANCER

A method for treating cancer comprising applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor CCR7, CCR5, CCR6, CCR8, CXCR4, CXCR7, CCR4, CCR9, CCR10, CXCR3 or CXCR5 or to a Treg receptor immobilized directly or indirectly on the support thus removing one or more chemokine receptor, optionally CCR7, CCR5, CCR6, CCR8, CXCR4, CXCR7, CCR4, CCR9, CCR10, CXCR3 or CXCR5 or Treg receptor expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described. 1. A method for treating cancer in a subject in need thereof , which comprises applying peripheral blood from the subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor selected from CCR7 , CCR5 , CCR6 , CCR8 , CXCR4 , CXCR7 , CCR4 , CCR9 , CCR10 , CXCR3 or CXCR5 immobilized directly or indirectly on the support , whereby one or more cells expressing chemokine receptors CCR7 , CCR5 , CCR6 , CCR8 , CXCR4 , CXCR7 , CCR4 , CCR9 , CCR10 , CXCR3 or CXCR5 are removed from the peripheral blood of the subject and the cancer is treated.2. The method of claim 1 , wherein the levels of circulating tumour cells are reduced in the subject.3. The method of claim 1 , wherein the incidence of tumour metastasis is reduced in the subject.4. The method of claim 1 , wherein the cancer is a leukaemia.5. The method of claim 4 , wherein the leukemia is selected from chronic lymphocytic leukaemia claim 4 , chronic myeloid leukemia claim 4 , acute myeloid leukemia (AML acute lymphoblastic leukemia (ALL) and leukemic phase of lymphoma.6. The method of claim 1 , wherein the binding reagent is an agonist or an antagonist of CCR7 claim 1 , CCR5 claim 1 , CCR6 claim 1 , CCR8 claim 1 , CXCR4 ...

Treating mental disorders

A method for treating mental disorders such as schizophrenia, depression and bipolar disorder comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising a binding reagent capable of specifically binding to a chemokine receptor, optionally the chemokine receptor CCR9, CCR1, CCR3 and/or CCR5 immobilized directly or indirectly on the support thus removing chemokine receptor, optionally CCR9, CCR1, CCR3 and/or CCR5 expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described.

BLOOD FILTRATION SYSTEM CONTAINING MANNOSE COATED SUBSTRATE

A blood filtration method, system, device and media for removing gram negative bacteria from the blood wherein the media includes a substrate coated with mannose optionally in constitution with substrate coated with heparin. 1. A method for attaching a mannose to an amine containing substrate , said method comprising:contacting an aminated substrate with an aqueous solution containing a mannose to form a Schiff base intermediate; andcontacting the Schiff base with a reducing agent to attach said mannose.2. The method of claim 1 , wherein said mannose is a reducing sugar.3. The method of claim 1 , wherein said mannose is a nonreducing sugar.4. The method of claim 1 , wherein said mannose is a member selected from the group consisting of D-mannose claim 1 , L-mannose claim 1 , p-aminophenyl-α-D-mannopyranoside claim 1 , a mannose containing polysaccharide and mannan.5. The method of claim 4 , wherein said mannose is D-mannose.6. The method of claim 4 , wherein said mannose is mannan.7. The method of claim 1 , wherein said mannose is a nonreducing sugar.8. The method of claim 4 , wherein said method further comprises attaching an intermediate aldehyde to the amine substrate prior to said nonreducing mannose.9. The method of claim 1 , wherein said aqueous solution is acidic.10. The method of claim 1 , wherein said aminated substrate is an aminated bead.11. The method of claim 1 , wherein said reducing agent is a member selected from sodium cyanoborohydride and sodium borohydride.12. The method of claim 1 , wherein said method further comprises reacting heparin having a reactive aldehyde functionality.13. A bead having end point attached mannose made according to the method of .14. A bead having end point attached mannose and heparin made according to the method of . The present application is a divisional of U.S. patent application Ser. No. 14/973,617, filed Dec. 17, 2015 which is a continuation of PCT/US2014/043358, filed Jun. 20, 2014, which application claims ...

POROUS CARBON STRUCTURE PRODUCTION

A process is provided for producing a structure into which blood or other bio-fluids can flow by capillary action, e.g. for a whole blood microsampling probe. The process comprises mixing particles of novolak resin and particles of hydrocarbon polymer, producing an uncarbonized structure from the mixture by pressurised moulding and carbonizing the moulded structure, the hydrocarbon resin being a polymer such as polystyrene that on pyrolysis has a zero carbon yield, and the particles of the hydrocarbon polymer leaving voids in the carbonized structure of sufficient size for flow of whole blood into and through the structure. The particles may be of partly cured and milled novolak resin, the novolak particles when in the moulded structure not exhibiting bulk flow during carbonization but sintering at inter-particle contact points during carbonization to provide a consolidated structure. In this variant, ethylene glycol may be used as a sintering aid. Alternatively, the particles may be of fully cured and milled novolak resin, and are mixed with the hydrocarbon polymer , the lubricant and with a binder such as lignin for providing a consolidated structure. 1. A process for producing a structure into which blood or other bio-fluids can flow by capillary action , said process comprising:mixing particles of novolak resin and particles of hydrocarbon polymer;producing an uncarbonized structure from the mixture by pressurised moulding; andcarbonizing the moulded structure, the hydrocarbon polymer being a polymer that on pyrolysis has a zero carbon yield, and the particles of the hydrocarbon polymer leaving voids in the carbonized structure of sufficient size for flow of whole blood into and through the structure to be enhanced.2. The process of claim 1 , wherein the particles of novolak resin are of mean size 40-70 μm and have been classified to remove powder of size less than 20 μm.3. The process of claim 1 , wherein the particles of hydrocarbon polymer have a mean ...

Selective cytopheresis devices and related methods thereof

The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.

APPARATUS FOR CARRYING OUT AN APHERESIS TREATMENT

The present invention relates to an apparatus for carrying out an apheresis treatment, wherein the apparatus has an extracorporeal circuit in which a regenerable single adsorber is located for separating substances from blood or for separating substances from plasma acquired by means of a plasma separator, wherein a line is provided for conducting the blood or the plasma which extends to the adsorber and via which blood or plasma is applied to the adsorber, wherein a reservoir is provided for receiving blood or plasma and is arranged upstream of the adsorber in the line or is in communication with the line upstream of the adsorber; and in that a controller or switching means is provided which is configured such that the reservoir is filled with blood or plasma and the application of blood or plasma to the adsorber is suppressed when the regeneration of the adsorber is carried out. 1. An apparatus for carrying out an apheresis treatment , wherein the apparatus has an extracorporeal circuit in which a regenerable single adsorber is located for separating substances from blood or for separating substances from plasma acquired by means of a plasma separator , wherein a line is provided for conducting the blood or the plasma which extends to the adsorber and via which blood or plasma is applied to the adsorber , characterized in that a reservoir is provided for receiving blood or plasma and is arranged upstream of the adsorber in the line or is in communication with the line upstream of the adsorber; and in that a controller or switching means is provided which is configured such that the reservoir is filled with blood or plasma and the application of blood or plasma to the adsorber is suppressed when the regeneration of the adsorber is carried out.2. An apparatus in accordance with claim 1 , characterized in that a first extracorporeal circuit is provided in which the plasma separator is located whose secondary side is adjoined by a second extracorporeal circuit claim 1 ...

EXTRACORPOREAL BLOOD CIRCULATION SYSTEM PROVIDED WITH BLOOD PURIFICATION DEVICE AND BLOOD COMPONENT ADJUSTER

An extracorporeal blood circulation device is provided with: a blood component adjuster; a blood purification device; a pipe system provided with a pump for supplying blood from a blood collecting part to the blood component adjuster, a valve for supplying a physiological saline solution, and a pressure gauge for sensing a pressure loss; a bypass pipe system for bypassing the blood component adjuster and supplying blood to the blood purification device; a pipe system for connecting the blood component adjuster and the blood purification device, the pipe system being provided with a pressure gauge for sensing a pressure loss; a pipe system provided with a valve for returning blood from the blood purification device to a reinfusion part and recovering the physiological saline solution, and a pressure gauge for sensing a pressure loss; and a control unit for switching to the bypass pipe system and switching to a reinfusion mode.

Therapeutic Detoxification Compositions and Methods of Making and Using Same

A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin. 1. A composition for use in the treatment of an autoimmune disease where a first component comprises a bimodal synthetic carbon particle mixture; a second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and a third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.2. The composition of where the components are separated.3. The composition of wherein the bimodal synthetic carbon particle mixture comprises a first carbon particle having pore size x and a second carbon particle having pore size y where y is greater than x.4. The composition of where y is two times x.5. The composition of wherein the second component has a ratio of bimodal synthetic carbon particle mixture to anion exchange resin of from about 1:1 to about 5:2.6. The composition of wherein the third component has a ratio of bimodal synthetic carbon particle mixture to cation exchange resin of from about 1:1 to about 5:1.7. A method comprising contacting a bodily fluid with the composition comprising:a first component comprising a bimodal synthetic carbon particle mixture;a second component comprising a bimodal synthetic carbon particle mixture and an anion exchange resin; anda third component comprising a bimodal synthetic carbon particle mixture and a cation exchange resin.8. The method of wherein contacting occurs in an extracorporeal apparatus having a first column claim 12 , a second column claim 12 , and a third column.9. The method of wherein the first component is disposed within the first column claim 13 , the second component is disposed within ...

PARALLEL PROCESSING OF FLUID COMPONENTS

A kit for blood component processing comprising a fluid circuit into which blood is drawn, wherein the fluid circuit comprises a plurality of pathways; wherein the first pathway is configured to receive blood drawn from a blood source and leads to a separation device, wherein the separation device is configured to separate the blood into components; wherein the second pathway is configured to receive a first component from the separation device and transport at least a portion of the first component to a first processing device, wherein the first processing device may alter the first component to produce a first output; and wherein the third pathway is configured to receive a second component from the separation device and transport at least a portion of the second component to a second processing device, wherein the second processing device may alter the second component to produce a second output. 1. A disposable kit for blood component processing comprising:a fluid circuit into which blood is drawn from a blood source, wherein the fluid circuit comprises a first, second, and third pathway;wherein the first pathway is configured to receive blood drawn from the blood source and leads to a separation device, wherein the separation device is configured to separate the blood into two or more components;wherein the second pathway is configured to receive a first component from the separation device and transport at least a portion of the first component to a first processing device, wherein the first processing device is configured to alter the first component in at least one of volume, constitution, and composition, to produce a first output; andwherein the third pathway is configured to receive a second component from the separation device and transport at least a portion of the second component to a second processing device, wherein the second processing device is configured to alter the second component in at least one of volume, constitution, and composition, to ...

POLYMERS FOR REVERSING HEPARIN-BASED ANTICOAGULATION

Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules. 1 {'sub': '1-18', 'sup': '1', 'claim-text': {'sup': '1', 'wherein each Ris independently selected from a polymer segment having monomer units of Formula (III), 'a core unit, wherein the core unit comprises a Calkyl substituted with three or more of —OR,'}, 'administering a heparin binding polymer to the subject, wherein the heparin binding polymer comprises. A method of counteracting heparin in a subject, the method comprising: wherein n is an integer from 1 to 10,000,', {'sup': 2', '1, 'wherein each Ris independently selected from a hydrogen, carbon, a cationic moiety, R, and a polymer segment of Formula (IV)]}}} [{'sup': '3', 'wherein each Ris independently selected from an oxygen cationic moiety, a hydroxyl, and a polymer segment of Formula (IV),'}, 'wherein m is an integer from 1 to 10,000,', {'sup': '4', 'sub': '1-6', 'wherein each Ris independently selected from a Calkoxy, and'}]}}}wherein the heparin binding polymer comprises 1 to 300 cationic moieties. This application is a continuation under 35 U.S.C. § 120 of U.S. application Ser. No. 15/887,561, filed Feb. 2, 2018, which is a continuation under 35 U.S.C. § 120 of U.S. application Ser. No. 14/629,408, filed on Feb. 23, 2015, now U.S. Pat. No. 10,111,902, which is a continuation under 35 U.S.C. § 120 of U.S. application Ser. No. 14/098,184, filed on Dec. 5, 2013, now U.S. Pat. No. 9,095,666, which is a divisional under 35 U.S.C. § 121 of U.S. application Ser. No. 13/458,899, filed on Apr. 27, 2012, now U.S. Pat. No. 8,637,008, which is a continuation under 35 U.S.C. § 120 of U.S. application Ser. No. 13/504,841, filed on Apr. 27, 2012, now U.S. Pat. No. 8,519,189, which was the U.S. National Phase entry ...

THERAPEUTIC COMPOSITIONS FOR VIRAL-ASSOCIATED DISEASE STATES AND METHODS OF MAKING AND USING SAME

A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject. 2. The method of wherein the subject is diagnosed with or suspected of having at least one virus of a plurality of viruses associated with immunosuppressive events.3. The method of wherein the at least one virus is a member of a viral family selected from the group consisting of Arenaviridae claim 2 , Bunyaviridae claim 2 , Filoviridae claim 2 , Flaviviridae claim 2 , Coronavirinae claim 2 , and Orthomyxoviridae.4. The method of wherein the subject is diagnosed with or suspected of having Hantavirus claim 2 , MERS-coronavirus (MERS-CoV) claim 2 , SARS-coronavirus (SARS-CoV-1) claim 2 , SARS-coronavirus (SARS-CoV-2) claim 2 , Influenza A virus subtype H5N1 claim 2 , Influenza A (H1N1) virus claim 2 , Ebola Virus claim 2 , Marburg virus claim 2 , or a combination thereof.5. The method of further comprising sanitizing the SCP claim 1 , the anion exchange resin claim 1 , and the cation exchange resin prior to contacting with the bodily fluids.6. The method of further comprising contacting the SCP claim 1 , the anion exchange resin claim 1 , and the cation exchange resin with a compatibilizer prior to contacting the SCP claim 1 , the anion exchange resin claim 1 , and the cation exchange resin with the bodily fluids.7. The method of wherein the compatibilizer comprises a polysaccharide ...

FILTER CONTAINER FOR SEPARATING CELLS AND FILTER DEVICE FOR SEPARATING CELLS

A filter container for separating cells includes a tubular filter member-housing part having an opening at each longitudinal end, a liquid inlet port on a first opening end side of the filter member-housing part, a liquid outlet port on a second opening end side of the filter member-housing part, a first filter-pressing part on the first opening end side, and a second filter-pressing part on the second opening end side. The first filter-pressing part includes three or more first protrusions, and the ratio of an area of a polygon formed by individually connecting the tips of the three or more first protrusions to a cross-sectional area of an inner space of the filter member-housing part at the first protrusion position is controlled within a preset range. 1. A filter container for separating cells , comprising:a liquid inlet port;a liquid outlet port;a filter member-housing part;a first filter-pressing part; anda second filter-pressing part,wherein the filter member-housing part is a tubular member having an opening at each longitudinal end,wherein the liquid inlet port is provided on a first opening end side of the filter member-housing part, and the liquid outlet port is provided on a second opening end side of the filter member-housing part,wherein the first filter-pressing part is located on the first opening end side and comprises three or more first protrusions protruding from an inner wall face of the filter member-housing part, or protruding from the vicinity of the inner wall face, toward a center or approximate center of a cross-section of an inner space of the filter member-housing part,wherein the first filter-pressing part is disposed such that, when a filter member is housed in the filter member-housing part, the first filter-pressing part is in contact with the filter member while deforming the filter member,wherein the second filter-pressing part is located on the second opening end side such that the filter member is interposed between the first ...

POLYMERS FOR REVERSING HEPARIN-BASED ANTICOAGULATION

Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules. 173.-. (canceled)74. A method of processing a subject's blood , the method comprising:providing a heparin binding device, the device comprising:a support; and a first dendritic polyol; and', 'one or more cationic moieties attached to the first dendritic polyol;, 'a heparin binding polymer immobilized on the support, wherein the heparin binding polymer compriseswithdrawing blood from a subject;contacting the blood to the heparin binding polymer; andreturning at least part of the blood to the subject, thereby processing the subject's blood.75. The method of claim 74 , wherein the subject's blood contains heparin.76. The method of claim 75 , wherein the heparin is exogenous heparin.77. The method of claim 76 , wherein the exogenous heparin binds to the heparin binding polymer and is thereby at least partially removed from the subject's blood.78. The method of claim 76 , further comprising the step of selecting a heparin binding polymer based upon the type of exogenous heparin administered to the subject.79. The method of claim 78 , wherein a heparin binding polymer of a particular molecular weight is selected based upon the type of exogenous heparin.80. The method of claim 78 , wherein a heparin binding polymer comprising a particular number of cationic groups is selected based upon the type of exogenous heparin.81. The method of claim 78 , wherein the heparin binding polymer works for a majority of heparins or all heparins.82. The method of claim 77 , wherein returning at least part of the blood to the subject further comprises fortifying the blood with one or more blood constituents that also bind to the heparin binding protein claim 77 , wherein the fortifying is ...

CEREBROSPINAL FLUID PURIFICATION SYSTEM

The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a catheter flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents. 1. A method for ameliorating a symptom of multiple sclerosis in a patient , said method comprising:selecting a patient having a symptom of multiple sclerosis;removing cerebrospinal fluid from a first location in a lumbar cerebrospinal fluid space of the patient;removing a causative agent from the removed cerebrospinal fluid, thereby conditioning the cerebrospinal fluid; andreturning the conditioned cerebrospinal fluid to the patient at a second location in a cervical cerebrospinal fluid space, a thoracic cerebrospinal fluid space, or a ventricle of the patient, wherein the cerebrospinal fluid is returned to the patient at substantially the same flow rate at which it is removed;wherein the removing and returning steps are performed concurrently using one or more catheters, each catheter comprising one or more lumens.2. A method as in claim 1 , wherein the one or more catheters comprises a single catheter comprising a first lumen with a first proximal port at the first location and a second lumen having a second distal port at the second location during at least a portion of a conditioning treatment.3. A method as in claim 1 , wherein the one or more catheters comprises a first catheter inserted at the first location and a second catheter inserted at the second location during at least a portion of a conditioning treatment.4. A method as in claim 3 , wherein the first catheter ...

Method for slowing the aging process

A method of slowing the aging process by extracorporeally treating a patient's blood is described. Certain antigens are known to be associated with aging. The method targets these antigens by complexing them with chemicals that facilitate removal of the antigens from the blood. The blood is removed from the patient, treated with a complexing agent, and then removed from the extracorporeal blood before the blood is returned to the patient. Targeted antigens can include mTOR (mammalian target of rapamycin), insulin growth factor-1 (IGF-1, insulin-like growth factor-1, somatomedin C), lipofuscin, p16 (p16INK4a, CDKN2A, cyclin-dependent kinase inhibitor 2A), SA-beta-gal (senescence-associated beta-gal), PML (promyelocytic leukemia) protein, TGF-β (transforming growth factor-beta), interleukin-6 (IL-6), indoleamine 2,3-dioxygenase, sTNF-R55 (soluble tumor necrosis factor-receptor 55), sTNF-R75 (soluble tumor necrosis factor-receptor 75), progerin, oxygen free radicals (e.g., superoxide, nitric oxide, hydroxyl radical, peroxynitrite, nitrosoperoxycarbonate, hydrogen peroxide, hypochlorite), malondialdehyde (MDA, propanedial), tumor necrosis factor-alpha (TNF-a), and mitogen-activated protein kinases (MAPKs). 1. A method for slowing aging comprising:a. removing a body fluid from a patient;b. applying a treatment to the body fluid that targets an antigen associated with aging; andc. returning the body fluid to the patient in a third stage.2. The method of claim 1 , wherein the method includes removing the treatment from the body fluid.3. The method of claim 1 , wherein the antigen is selected from the group consisting of mTOR claim 1 , insulin growth factor-1 claim 1 , lipofuscin claim 1 , p16 claim 1 , SA-beta-gal claim 1 , PML protein claim 1 , TGF-beta claim 1 , interleukin-6 claim 1 , indoleamine 2 claim 1 ,3-dioxygenase claim 1 , sTNF-R55 claim 1 , sTNF-R75 claim 1 , progerin claim 1 , an oxygen-containing free radical claim 1 , malondialdehyde claim 1 , tumor necrosis ...

TREATING CONDITIONS ASSOCIATED WITH METABOLIC SYNDROME

A method for treating a condition associated with metabolic syndrome or for treating adiposis dolorosa (AD) comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor CCR2, CCR1, CCR3, CCR4 or CCR5 immobilized directly or indirectly on the support thus removing one or more chemokine receptor, optionally CCR2, CCR1, CCR3, CCR4 and CCR5 expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described. 1. A method for treating a condition associated with metabolic syndrome or for treating adiposis dolorosa (AD) in a subject in need thereof , which comprises applying peripheral blood from the subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor selected from CCR2 , CCR1 , CCR3 , CCR4 and CCR5 immobilized directly or indirectly on the support , whereby one or more cells expressing chemokine receptors CCR2 , CCR1 , CCR3 , CCR4 and/or CCR5 are removed from the peripheral blood of the subject and the condition associated with metabolic syndrome or adiposis dolorosa (AD) is treated.2. The method of wherein the condition associated with metabolic syndrome is selected from diabetes claim 1 , obesity claim 1 , insulin resistance claim 1 , increased serum triacylglycerol concentrations claim 1 , and hypertension.3. The method of claim 1 , wherein the binding reagent is an agonist or an antagonist of CCR2 claim 1 , CCR1 claim 1 , CCR3 claim 1 , CCR4 or CCR5.4. The method of claim 1 , wherein the binding reagent is an antibody or a chemokine.5. The method of claim 4 , wherein(a) the chemokine is selected from MCP-1, MCP-2, MCP-3, MCP-4 and MCP-5 and the chemokine receptor is CCR2,(b) the chemokine is RANTES and ...

BLOOD CLEANSING AND APPARATUS & METHOD

The present invention relates to removing disease causing agent such as pathogens from the blood of a patient. Specifically, the invention relates to using coating materials to trap disease causing agent that is desired to be removed from the blood of a patient. It also related to using lights of specific wavelength to inactivate pathogens. The light is used to activate reactive oxygen species using a photo-sensitizer or directly kill the pathogen using light of wavelength between 100 nm and 450 nm. 1. An apparatus for removing disease causing agent from blood , said apparatus comprising:an inlet tube for flowing blood from a blood source;a pump connected to the tube;one or more cleansing chambers connected to the tube, wherein each of the cleansing chambers comprises an inlet, through which the blood flows in to the cleansing chamber, an outlet, through which the blood flows out of the cleansing chamber, an outlet, and an inner portion coated with a coating material; andan outlet tube connected to the outlet of the cleansing chamber which returns the blood to the blood source.2. The apparatus of claim 1 , wherein each of the cleansing chambers is one or more cleansing chambers selected from a group of cleansing chambers comprising tube claim 1 , parallelepiped claim 1 , rectangular parallelepiped claim 1 , and a cylinder.3. The apparatus of claim 1 , wherein the coating material is one or more coating materials selected from a group of coating material comprising antibodies claim 1 , adhesion molecules claim 1 , and pathogen killing molecules.4. The apparatus of claim 1 , further comprising one or more light sources each of which illuminate at least one of the one or more cleansing chambers.5. The apparatus of claim 4 , wherein the light sources generate light with one or more of wavelengths selected from a group of wavelengths comprising a wavelength centered at 207 nm claim 4 , a wavelength centered at 415 nm claim 4 , a wavelength centered at 400 nm claim 4 , a ...

Methods and apparatus for kidney dialysis and extracorporeal detoxification

The present disclosure relates to a dialysis apparatus comprising a membrane having at least one protein from the lipocalin family bound thereon. The disclosure further relates to methods of removing non-polar, hydrophobic and/or protein bound uremic toxins from a target subject utilizing the dialysis apparatus described herein as well as methods of extracorporeal detoxification.

Single Pass Dialysis Combined with Multiple Pass Albumin Dialysis

Methods, systems, and devices are disclosed, embodiments of which provide single pass dialysis to remove water and uremic toxins is performed simultaneously with the albumin dialysis therapy by passing the albumin solution through a dialysis filter which dialyses it before the solution is returned to the cycler. In embodiments, the single pass dialysis stage is upstream of the albumin filtering stage. 1. A method for simultaneously performing liver dialysis that clears albumin-bound molecules from blood and kidney dialysis that clears solutes from blood , the method comprising:providing a medical treatment cycler that includes a first pump and a second pump, the medical treatment cycler being configured to balance a medical treatment fluid flowing into the medical treatment cycler and the medical treatment fluid flowing out of the medical treatment cycler and adapted to provide a selectable difference between ingoing and outgoing flows of the medical treatment fluid;connecting the medical treatment cycler to a predefined disposable tubing set that includes a first filter, a fluid inlet connector, and a fluid outlet connector;providing a supplemental fluid management system configured to clear solutes from a solution received at the fluid outlet connector and to supply solute-cleared fluid to the fluid inlet connector, the supplemental fluid management system having a second filter;connecting the supplemental fluid management system to the fluid inlet connector and the fluid outlet connector of the predefined disposable tubing set;selecting the selectable difference between the ingoing and outgoing flows;controlling the first pump to operate at a first fluid flow rate;controlling the second pump to operate at a second fluid flow rate that differs from the first fluid flow rate by the selectable difference;circulating an albumin solution in the predefined disposable tubing set;clearing solutes from the albumin solution using the supplemental fluid management system; ...

COMPOSITIONS AND DEVICES FOR REMOVAL OF ENDOTOXINS AND CYTOKINES FROM FLUIDS

Provided are sorption materials and devices using the sorption materials, and methods of using the sorption materials and devices containing the sorption materials. In various examples, the sorption materials bind to various inflammation stimulating and/or mediating molecules, which are often associated with systemic infections and systemic inflammation associated with conditions such as, for example, sepsis. 2. The method of claim 1 , wherein the contacting comprises passing a biological fluid through a housing claim 1 , wherein the housing includes an inlet and an outlet claim 1 , wherein the inlet and the outlet are in fluid communication claim 1 , and the housing is configured such that the fluid enters the housing through the inlet and exits the housing through the outlet claim 1 , wherein the at least one sorption material is disposed in the housing.3. The method of claim 1 , wherein the method further comprises returning the biological fluid to the subject.4. The method of claim 1 , wherein the biological fluid is blood claim 1 , serum claim 1 , culture media claim 1 , or a combination thereof.5. The method of claim 1 , wherein the substrate is a hydrogel network or solid substrate.6. The method of claim 5 , wherein the solid substrate is porous.7. A device for removing inflammation stimulating and/or mediating molecules from a fluid comprising:a housing defining an inlet and an outlet, wherein the inlet and the outlet are in fluid communication with one another, and the housing is configured such that the fluid enters the housing through the inlet and exits the housing through the outlet; and {'br': None, 'sup': 1', '1', '2', '2, 'sub': 'x,y', 'R-L-D-(L-R)'}, 'a sorption material is disposed in the housing, wherein the sorption material comprises at least one compound bound to a substrate, wherein the compound has the following structure{'sup': 1', '1, 'claim-text': [{'sup': 1', '2, 'Land Lindependently at each occurrence are optional and are linker groups ...

METHOD AND APPARATUS FOR CONTINUOUS REMOVAL OF SUB-MICRON SIZED PARTICLES IN A CLOSED LOOP LIQUID FLOW SYSTEM

A centrifuge rotor having a curved shape is offset on a spinning rotor base and creates contiguous areas of low to high centrifugal force depending on the distances from the axis of the rotor base and a method of separating components in a fluid based upon a difference in density of the components, the method comprising the steps of providing to a rotor as described herein the fluid containing the mixed together components to be separated based upon the difference in density of the mixed together components; continuously flowing the components in the fluid to the rotor through an input tube connected to the input port while the rotor is spinning about a centrifugal axis of rotation; separating the components in the fluid into fractions based upon the difference in density of the mixed together components with the use of centrifugal force when the rotor is spinning; collecting components having i) a first density via a first tube connected to the output port at the first end on the rotor, ii) a second density via a second tube connected to the output port at the second end on the rotor, iii) a third density via a third tube connected to the output port at the junction on the rotor and iv) a fourth density via a fourth tube connected to the output port between the input port and the output port at the first end. 1. A rotor comprising:a hollow curved housing that has an inner wall and an outer wall, a top, a bottom and a first end and a second end wherein the inner wall is radially closer to an axis of rotation as compared to the outer wall;the hollow curved housing being formed of a curved first rotor element that terminates at the first end of the curved housing and a curved second rotor element that terminates at the second end of the curved housing wherein the curved housing between the curved first rotor element and the curved second rotor element includes a junction that creates a change in an inner and outer radius of the first rotor element as compared to an ...

SYSTEM FOR REMOVING UREMIC TOXINS IN DIALYSIS PROCESSES

A method of performing dialysis includes: recirculating a dialysis fluid from a patient or a dialyzer for at least two cycles, each cycle contacting the dialysis fluid first with a zirconium phosphate layer followed by at least one of a urease layer, a zirconium oxide layer, or a carbon layer; storing the recirculated dialysis fluid in a storage container; and transferring the dialysis fluid from the storage container to the patient or the dialyzer. In one example, the zirconium phosphate layer and the at least one of the urease layer, the zirconium oxide layer, or the carbon layer is provided by a sorbent cartridge. 1. A method of performing dialysis comprising:recirculating a dialysis fluid from a patient or a dialyzer for at least two cycles, each cycle contacting the dialysis fluid first with a zirconium phosphate layer followed by at least one of a urease layer, a zirconium oxide layer, or a carbon layer;storing the recirculated dialysis fluid in a storage container; andtransferring the dialysis fluid from the storage container to the patient or the dialyzer.2. The method of claim 1 , which includes operating valves to alternate between a cleaning cycle and a storing cycle.3. The method of claim 1 , wherein each cycle contacts the dialysis fluid first with a zirconium phosphate layer claim 1 , followed by a urease layer claim 1 , followed by at least one of a second zirconium phosphate layer claim 1 , a zirconium oxide layer claim 1 , and a carbon layer.4. The method of claim 3 , wherein each cycle contacts the dialysis fluid first with a zirconium phosphate layer claim 3 , followed by a urease layer claim 3 , followed by a second zirconium phosphate layer claim 3 , followed by a zirconium oxide layer claim 3 , followed by a carbon layer.5. The method of claim 1 , wherein the zirconium phosphate layer and the at least one of the urease layer claim 1 , the zirconium oxide layer claim 1 , or the carbon layer is provided by a sorbent cartridge.6. A method of ...

THE USE OF A HEMOCOMPATIBLE POROUS POLYMER BEAD SORBENT FOR REMOVAL OF PAMPS AND DAMPS

The invention concerns biocompatible polymer systems comprising at least one polymer sorbent with a plurality of pores, said polymer designed to adsorb pathogen-associated molecular pattern molecules and damage-associated molecular pattern molecules. Also disclosed herein are methods for reducing contamination in a biological substance, or treating contamination in a subject, by one or more pathogen-associated molecular pattern molecules and damage-associated molecular pattern molecules, by contacting the biological substance with an effective amount of sorbent capable of sorbing the toxin. 1. A biocompatible polymer system comprising at least one polymer , said polymer system capable of adsorbing (i) pathogen-associated molecular pattern molecules (PAMPS) and (ii) damage-associated molecular pattern molecules (DAMPS) having a molecular weight of from less than about 0.5 kDa to about 1 ,000 kDa.2. The biocompatible polymer system of wherein the polymer comprises a plurality of pores and the polymer's pore structure has a total volume of pore sizes in the range of from 50 Å to 40 claim 1 ,000 Å greater than 0.5 cc/g and less than 5.0 cc/g dry polymer.3. The biocompatible polymer system of wherein the polymer is hemocompatible.4. The biocompatible polymer system of wherein the geometry of said polymer system is a spherical bead.5. The biocompatible polymer system of wherein the toxins comprise PAMPs and DAMPS comprised of one or more of flagellins claim 1 , lipopeptides claim 1 , formyl peptides claim 1 , mycotoxins claim 1 , exotoxins claim 1 , endotoxins claim 1 , lipoteichoic acid claim 1 , cytolysins claim 1 , superantigens claim 1 , proteases claim 1 , lipases claim 1 , amylases claim 1 , enzymes claim 1 , peptides including bradykinin claim 1 , activated complement claim 1 , soluble receptors claim 1 , soluble CD40 ligand claim 1 , bioactive lipids claim 1 , oxidized lipids claim 1 , cellular DNA claim 1 , mitochondrial DNA claim 1 , pathogen or host derived RNA ...

Methods and apparatus for kidney dialysis and extracorporeal detoxification

The present disclosure relates to a dialysis apparatus comprising a membrane having at least one protein from the lipocalin family bound thereon. The disclosure further relates to methods of removing non-polar, hydrophobic and/or protein bound uremic toxins from a target subject utilizing the dialysis apparatus described herein as well as methods of extracorporeal detoxification. 131.-. (canceled)32. A method of dialysis to remove a nonpolar , hydrophobic , and/or protein-bound uremic toxin from the blood or plasma of a subject , comprising subjecting the blood or plasma to an apparatus comprising a body having an inlet and an outlet and defining an interior , the interior including at least one membrane having at least one protein from the lipocalin family bound thereon , the at least one protein being one that binds to the uremic toxin , the apparatus being arranged so that the blood or plasma entering the apparatus contacts the at least one protein from the lipocalin family bound to the at least one membrane in the interior of the apparatus.33. The method of claim 32 , where the at least one protein from the lipocalin family is selected from the group consisting of alpha-1-microglobulin (protein HC) claim 32 , major urinary proteins claim 32 , alpha-1-acid glycoprotein (orosomucoid) claim 32 , aphrodisin claim 32 , apolipoprotein D claim 32 , beta-lactoglobulin claim 32 , complement component C8 gamma chain claim 32 , crustacyanin claim 32 , epididymal-retinoic acid binding protein (E-RABP) claim 32 , insectacyanin claim 32 , odorant binding protein (OBP) claim 32 , human pregnancy-associated endometrial alpha-2 globulin (PAEP) claim 32 , probasin (PB) claim 32 , a prostatic protein claim 32 , prostaglandin D synthase claim 32 , purpurin claim 32 , Von Ebner's gland protein (VEGP) claim 32 , and lizard epididymal secretory protein IV (LESP IV).34. The method of claim 32 , where the at least one protein from the lipocalin family is selected from the group ...

BLOOD PURIFYING FILTER AND BLOOD PURIFYING APPARATUS

Provided are a blood purifying filter and a blood purifying apparatus having the same. The blood purifying filter includes a plasma separation filter separating plasma from blood, a hemodialysis filter configured in parallel with the plasma separation filter to remove toxins and waste products from blood, a housing providing installation space for the plasma separation filter and the hemodialysis filter, and plasma inlet and outlet ports provided in the housing. The housing further includes a wall, a lower cap and an upper cap which are coupled to the plasma separation filter and the hemodialysis filter. 1. A blood purifying filter comprising:a plasma separation filter separating plasma from blood;a hemodialysis filter removing toxins and waste products from blood;a housing providing installation space for the plasma separation filter and the hemodialysis filter and defining a plasma flow section outside the plasma separation filter and the hemodialysis filter,a plasma inlet port provided in the housing to allow separated plasma to flow into the plasma flow section; anda plasma outlet port provided in the housing to allow plasma having passed the plasma flow section to be discharged out of the blood purifying filter.2. The blood purifying filter of claim 1 , wherein the housing comprises:a wall having a cylindrical shape;a lower cap coupled to the plasma separation filter and the hemodialysis filter at a lower side of the wall; andan upper cap coupled to the plasma separation filter and the hemodialysis filter at an upper side of the wall.3. The blood purifying filter of claim 2 , wherein:the lower cap comprises a lower-cap insertion groove coupled to the plasma separation filter or the hemodialysis filter and a lower-cap passage which penetrates the lower cap, wherein one end of the lower-cap passage is connected to the lower-cap insertion groove; andthe upper cap comprises an upper-cap insertion groove coupled to the plasma separation filter or the hemodialysis ...

Integrated Leukocyte, Oxygen and/or CO2 Depletion, and Plasma Separation Filter Device

A blood filter device comprising: a housing comprising an outer wall and a first inlet, a first outlet and a second outlet; a membrane which is capable of separating plasma from the blood, wherein the membrane forms an inner chamber; a leukocyte and oxygen and/or carbon dioxide depletion media disposed wherein the inner chamber, the leukocyte and oxygen and/or carbon dioxide depletion media is capable of depleting leukocytes and oxygen and/or carbon dioxide from the blood; an outer chamber disposed between the outer wall and the membrane, wherein the plasma which permeates through the membrane enters the outer chamber and exits the filter device via the first outlet; whereby the blood which has been depleted of oxygen and/or carbon dioxide, leukocytes and plasma exists and filter device via the second outlet. 138.-. (canceled)39. A method for processing blood , comprising: a housing comprising an outer wall, a first inlet, a first outlet and a second outlet;', 'a membrane which is capable of separating plasma from said blood, wherein said membrane forms at least one inner chamber within said housing and said blood enters said at least one inner chamber of said blood filter device through said first inlet;', 'a leukocyte, carbon dioxide, and oxygen depletion media disposed within said at least one inner chamber, said leukocyte, carbon dioxide, and oxygen depletion media is capable of depleting leukocytes, carbon dioxide and oxygen from said blood; and', 'an outer chamber disposed between said outer wall and said membrane,, 'passing said blood through a blood filter device comprisingseparating said plasma from said blood by permeating through said membrane, wherein said plasma enters said outer chamber and exits said housing via said first outlet; anddepleting oxygen, leukocytes and plasma from said blood, whereby oxygen, leukocytes and plasma depleted blood exits said housing via said second outlet as packed red blood cells (pRBCs).40. The method according to claim ...

DEVICE AND METHOD FOR REMOVING UNDESIRABLE BIOLOGICAL AND/OR CHEMICAL ENTITIES FROM BIOLOGICAL FLUIDS

A device removing a biological and/or chemical entity (C) from extracorporeal blood (B) is disclosed. The device has a hollow capture chamber with an inlet for the entry of the extracorporeal blood (B) and an outlet for the outflow of the extracorporeal blood (B) and a capture element inside the capture chamber having a reactant surface placed in contact with the extracorporeal blood (B) and a plurality of binding agents (A) for the biological and/or chemical entity to be removed (C) such that the biological and/or chemical entity (C), upon exiting the capture chamber, is removed from the extracorporeal blood (B) as linked to the reactant surface. 1. A method for the ex-vivo removal of a biological and/or chemical entity (C) from an extracorporeal blood volume (B) comprising: i) being rotatable about a longitudinal axis (a) of the capture chamber;', 'ii) having a reactant surface for contacting the extracorporeal blood (B),said reactant surface comprising a plurality of binding agents (A) for the biological and/or chemical entity to be removed (C), and', 'iii) a coupling and uncoupling system configured such that the capture element can be removed from the capture chamber to allow analysis of entities captured by the reactant surface,, 'a) introducing the extracorporeal blood (B) into a hollow capture chamber having a cylindrical shape, an inlet for the entry of the extracorporeal blood (B), an outlet for the outflow of the extracorporeal blood (B) and a capture element extending longitudinally within the capture chamber and movable relative to the capture chamber, the capture elementb) filtering the extracorporeal blood (B) by contact with the reactant surface having the plurality of binding agents (A) for the biological and/or chemical entity (C) to be removed; andc) extracting the extracorporeal blood (B) devoid of said biological and/or chemical entity (C) from the capture chamber;wherein the total volume of extracorporeal blood (B) flowing inside the capture ...

Platelet Storage Container

Compositions, methods, devices and media are provided for platelet storage container that prevents bacterial growth in the stored platelets. The invention relates to blood bank needs in safely storing platelets collected from donors for more than 5 days at room temperature. The container is built with natural adsorbent media that have the characteristics in capturing and killing bacteria and viruses. The stored platelets are isolated from the natural adsorbent material during storage to preserve their medical quality and safety. 1) A container used for platelets storage having outer walls for fluid containment whereas said outer walls are permeable to gases such as O2 and CO2 ,{'sup': '2', 'said container including one or more compartment extending from the inner surface of the outer wall and encompassing adsorbent media having a minimum surface area of 400 m/g,'}said compartment sharing one or more wall segments with the container outer wall and having other wall segments that are in direct contact with the stored fluid, said other wall segments are made of porous membranes that allow for fluid and pathogens to pass through while preventing blood cells including platelets from entering the compartment,said container is agitated in a movement suitable for platelet storage, fluids stored inside the container pass through the porous membrane wall segments in and out of said compartments, pathogens suspended in the stored fluid pass through the pores inside the compartments and contact the adsorbent media, whereas said pathogens are captured by the adsorbent media and isolated inside the compartments, therefore reducing the pathogen concentration in the stored fluid that is kept outside the compartments, the pathogen depleted platelet concentrate solution that is kept outside the compartments is used for transfusion.2) The platelet storage container defined in wherein said adsorbent media is activated carbon particulates.3) The platelet storage container defined in ...

FIBER MATERIAL AND PURIFICATION COLUMN

A fibrous material includes fiber blends having plural types of solid fibers having a common cross-sectional shape. The composition ratio of each of at least two out of the plural types of fibers to the total of the fiber blends is not less than 5.0%. When, among those plural types of fibers having a composition ratio of not less than 5.0%, fibers having the highest and the lowest surface area increase rates, which are given by the formula (1) below, are respectively designated as the fiberand the fiber, the surface area increase rate of the fiberis reduced by 3.0% or more as compared to that of the fiber. The composition ratios of the fiberand the fiberto the total of the fiber blends are not less than 30.0% and not less than 8.0%, respectively. The fiberhas (a) a surface area increase rate of not less than 1.20 and is (b) a porous fiber with a micropore specific surface area of not less than 5 m/g. 1. A fibrous material comprising fiber blends having plural types of solid fibers having a common cross-sectional shape , wherein the composition ratio of each of at least two out of the plural types of fibers to the total of the fiber blends is not less than 5.0% , and when , among those plural types of fibers having a composition ratio of not less than 5.0% , fibers having the highest and the lowest surface area increase rates , which are given by the formula (1) below , are respectively designated as the fiberand the fiber , the surface area increase rate of the fiberis reduced by 3.0% or more as compared to that of the fiber , and the composition ratios of the fiberand the fiberto the total of the fiber blends are not less than 30.0% and not less than 8.0% , respectively , and the fiberhas (a) a surface area increase rate of not less than 1.20 and is (b) a porous fiber with a micropore specific surface area of not less than 5 m/g{'br': None, 'Surface area increase rate=(the circumference of a fiber cross section)/(the circumference of a circle having the same cross- ...

WEARABLE HEMOPERFUSION DEVICE

The present technology relates to methods and devices for the removal of toxins and pathogens from infected blood of patients. In particular, devices are designed to be portable, wearable, disposable and self-contained extracorporeal devices that can be easily assembled from a kit. 1. A portable and/or wearable device for extracorporeal removal of a toxin and/or pathogen from blood of an individual infected with the toxin and/or pathogen , the device comprising a cartridge , said cartridge comprising an adsorption media ,wherein the adsorption media is a solid substrate of high surface area having at least one polysaccharide adsorbent on the surface thereof with a binding affinity or binding site for the toxin and/or pathogen such that when the flowing blood is in contact with said adsorption media, the toxin and/or pathogen bind to binding sites on the at least one polysaccharide adsorbent and become separated from blood.2. A portable and/or wearable extracorporeal hemoperfusion device , the device comprising:a cartridge comprising adsorption media, the cartridge having a first endplate and a second endplate;a blood influx port to allow blood to flow into the device; anda blood efflux port to allow blood to flow out of the device, wherein the blood flows through the first endplate through the adsorption media and out the blood efflux port.3. The portable and/or wearable device of claim 2 , further comprising a pump.4. The portable and/or wearable device of claim 3 , wherein the pump is a rotary pump.5. The portable and/or wearable device of claim 2 , further comprising a power source.6. The portable and/or wearable device of claim 2 , further comprising an electronic control module.7. The portable and/or wearable device of claim 6 , wherein the power source or the electronic control module are detachable.8. The portable and/or wearable device of claim 1 , wherein the least one polysaccharide adsorbent is selected from the group consisting of heparin claim 1 , ...

PROCESS FOR REMOVING LEAD IONS FROM BOLDILY FLUIDS USING METALLATE ION EXCHANGE COMPOSITIONS

A process for removing Pb toxins from bodily fluids is disclosed. The process involves contacting the bodily fluid with an ion exchange composition to remove the metal toxins in the bodily fluid, including blood and gastrointestinal fluid. Alternatively, blood can be contacted with a dialysis solution which is then contacted with the ion exchange composition. The ion exchange compositions are represented by the following empirical formula: 2. The process of wherein the bodily fluid is selected from the group consisting of whole blood claim 1 , blood plasma claim 1 , or other component of blood claim 1 , gastrointestinal fluids claim 1 , dialysate fluids claim 1 , gastrointestinal fluids and dialysate solution containing blood claim 1 , blood plasma claim 1 , other component of blood or gastrointestinal fluids.3. The process of where the ion-exchanger has the phamacosiderite topology.4. The process of where the ion-exchanger has the sitinakite topology.5. The process of where the ion-exchanger is an intergrowth of the phamacosiderite and sitinakite topologies.6. The process of where the ion-exchanger is a composite comprised of a mixture of the phamacosiderite claim 1 , sitinakite claim 1 , pharmacosiderite-sitinakite intergrowth topologies in any combination.7. The process of where a=1.8. The process of where A is hydronium (H).9. The process of where A is calcium.10. The process of where A is sodium.11. The process of where A is a mixture of hydronium (H) claim 1 , calcium and sodium.12. The process of wherein said ion exchanger is formed into a shaped article to be ingested orally claim 1 , followed by ion exchange between said ion exchanger and said Pb toxins contained in a gastrointestinal fluid in a mammal's intestines and then by excretion of said ion exchanger containing said toxins.14. The composition of wherein said bodily fluid is whole blood claim 13 , blood plasma claim 13 , other blood component or gastrointestinal fluid.16. The apparatus of wherein ...

Extracorporeal removal of microvesicular particles

The invention described herein teaches methods of removing microvesicular particles, which include but are not limited to exosomes, from the systemic circulation of a subject in need thereof with the goal of reversing antigen-specific and antigen-nonspecific immune suppression. Said microvesicular particles could be generated by host cells that have been reprogrammed by neoplastic tissue, or the neoplastic tissue itself. Compositions of matter, medical devices, and novel utilities of existing medical devices are disclosed.

Non-hemolyzing blood filter and methods for filtering blood without hemolysis

An article, system, and method is provided for the filtration of blood wherein the blood is removed, contacted with a filter substrate operatively associated with a filter structure, and the filtered blood is subsequently returned to a receiver. Methods for removing iron from the liquid fraction of blood and for determining whether a substrate is capable of selectively retaining 2,2′-dipyrydyl (DP)-Fe 2+ complexes are also disclosed.

WHOLE BLOOD TREATMENT DEVICE AND METHODS OF REMOVING TARGET AGENTS FROM WHOLE BLOOD

A whole blood treatment device includes a cartridge configured to receive whole blood, having a wall defining an interior volume, an inlet, and an outlet, a support structure having a surface, inside of the cartridge, and an affinity agent, attached to the surface of the support structure. The affinity agent is effective to bind to a target agent that is desirable for removal from a patient. The target agent is selected from the group consisting of: inhibitory checkpoint molecules, inflammatory factors, cancerous cells, autoantibodies, opioids and heavy metals. A method of removing a target agent from whole blood of a patient in a whole blood treatment device comprising pumping whole blood into a cartridge, containing a support structure having a surface, with a plurality of affinity agents on the support structure, to contact the whole blood with the affinity agents; binding the target agent with the affinity agents; and removing the whole blood having a reduced amount of the target agent from the cartridge. The target agent is selected from the group consisting of: inhibitory checkpoint molecules, inflammatory factors, cancerous cells, autoantibodies, opioids and heavy metals. 1. A whole blood treatment device for treating a patient , comprising:a cartridge configured to receive whole blood, having a wall defining an interior volume, an inlet, and an outlet,a support structure having a surface, in the cartridge, andan affinity agent attached to the surface of the support structure,wherein the affinity agent is effective to bind a target agent, andthe target agent is selected from the group consisting of: inhibitory checkpoint molecules, inflammatory factors, cancerous cells, autoantibodies, opioids and heavy metals.2. The whole blood treatment device of claim 1 , wherein the target agent is at least one inhibitory checkpoint molecule selected from the group consisting of: cytotoxic T-lymphocyte associated protein 4 (CTLA-4) claim 1 , programmed cell death-1 (PD-1) ...

CARTRIDGE AND METHOD FOR INCREASING MYOCARDIAL FUNCTION

The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions that affect myocardial function and to related methods. The cartridge can be used in treating a subject with myocardial dysfunction, such as a subject with chronic heart failure and/or acute decompensated heart failure. 1. A method of increasing myocardial function in a subject with chronic heart failure , the method comprising: (i) a rigid housing defining an inner volume (IV), a fluid inlet port and a fluid outlet port, wherein the inner volume is in fluid flow communication with the fluid inlet port and the fluid outlet port, and', '(ii) a solid support disposed within the housing and defining a fluid contacting surface with a surface area (SA) capable of sequestering activated leukocytes and/or activated platelets, if present in a body fluid entering the housing via the fluid inlet port, and the body fluid is introduced into the housing via the fluid inlet port under conditions that permit sequestration of the activated leukocytes and/or activated platelets on the fluid contacting surface of the solid support; and, '(a) extracorporeally sequestering activated leukocytes and/or activated platelets present in a body fluid of the subject in a cartridge comprising'}(b) treating the sequestered leukocytes and/or platelets to inhibit release of a pro-inflammatory substance or to deactivate the leukocytes and/or platelets thereby to increase myocardial function of the subject when compared to the myocardial function of the subject prior to treatment, wherein the myocardial function is selected from the group consisting of left ventricular ejection fraction, cardiac output, systemic vascular resistance, left ventricular stroke volume, aortic pressure, left ventricular pressure, peak rate of change of left ventricular pressure during isovolumic contraction and relaxation, left ventricular end-diastolic pressure, myocardial oxygen consumption, and ...

NON-HEMOLYZING BLOOD FILTER AND METHODS FOR FILTERING BLOOD WITHOUT HEMOLYSIS

An article, system, and method is provided for the filtration of blood wherein the blood is removed, contacted with a filter substrate operatively associated with a filter structure, and the filtered blood is subsequently returned to a receiver. Methods for removing iron from the liquid fraction of blood and for determining whether a substrate is capable of selectively retaining 2,2′-dipyridyl (DP)-Fe complexes are also disclosed. 1. A system for filtering blood comprising:a vessel configured to selectively hold a volume of blood; 'wherein the more than one substrate are arranged in series at an outlet of the vessel; and', 'more than one substrate configured to chemically filter the blood and blood components,'}{'sup': 2+', '2+, 'at least one structure configured to support said more than one substrate, wherein the at least one substrate is configured to selectively retain 2,2′-dipyridyl (DP)-Fe complexes but is permeable to Arsenazo III-Ca complexes, and wherein said at least one structure has a pore size between 0.0001 micron to 20 micron.'}2. The system of claim 1 , wherein said more than one substrate is independently:a chelating agent;a styrene-divinylbenzene co-polymer containing iminodiacetic acid groups;polyphenols;phytates;ascorbic acid derivatives;polymeric hydroxamic acid;derivatives/hydrogels/resins, or chemical modifications of existing oral chelating drugs—deferoxamine, deferiprone, and deferasirox, or combinations thereof.3. The system of wherein said more than one substrate is positioned in-line in a blood transfusion system.4. The system of wherein blood claim 3 , in the blood transfusion system claim 3 , is caused to make contact with said more than one substrate by gravitational movement of blood claim 3 , mechanical movement of blood claim 3 , or a combination thereof. This application claims the benefit of U.S. Provisional Patent Application No. 61/816,061, filed Apr. 25, 2013, the entire contents of which are hereby incorporated by reference. ...

METHOD FOR SUPPRESSING SURGICAL SITE INFECTION AND COLUMN TO BE USED FOR THE METHOD

An object of the present invention is to provide a method for suppressing surgical site infections (SSI) that have occurred at extremely high incidence rates at the time of surgical operations and particularly surgical operations on digestive system organs, and to provide a column to be used for the method. According to the present invention, a method is provided for suppressing surgical site infections, which comprises the steps of: (a) administering a chemotherapeutic drug for treating and/or preventing a surgical site infection; and (b) collecting blood from a surgical subject and removing leukocytes that comprise neutrophils from the blood during or within 24 hours after surgical operation, and then returning the blood from which the leukocytes have been removed to the surgical subject. The present invention also provides a column for blood circulation which is filled with a carrier having affinity for leukocytes comprising neutrophils, which is used for suppressing a surgical site infection during or within 24 hours after surgical operation on a digestive system organ. 1. A blood processing method for a surgical subject , wherein leukocytes comprising neutrophils are removed from the blood of a surgical subject during or within 24 hours after surgical operation on a digestive system organ.2. The blood processing method for a surgical subject according to claim 1 , wherein the number of leukocytes that comprise neutrophils and are removed is 6×10or more and 1×10or less per kg of the body weight of the surgical subject.3. The blood processing method for a surgical subject according to claim 1 , wherein the digestive system organ is selected from among the esophagus claim 1 , stomach claim 1 , small intestine claim 1 , large intestine claim 1 , rectum claim 1 , colon claim 1 , appendix claim 1 , liver claim 1 , pancreas claim 1 , and gallbladder.4. The blood processing method for a surgical subject according to claim 1 , wherein the surgical subject is a patient ...

BLOOD PURIFIER AND METHOD FOR MANUFACTURING SAME

Provided is a blood purifier which has a porous molded body with good phosphorus adsorption, which has good cytokine adsorption performance, no hemolysis, and can be used safely. The blood purifier has a porous molded body having a low-melting-point moisture content per gram of dry weight of 0.12 g or more and 1.35 g or less. After three and six months from sealing of a saline solution for injection into the blood purifier, the number of microparticles greater than or equal to 10 μm is 25 or less and the number of microparticles greater than or equal to 25 μm is three or less in 1 mL of the saline solution for injection. 1. A blood purification device comprising a porous molded body having a low-melting-point moisture content of 0.12 g to 1.35 g per gram of dry weight , wherein the number of microparticles of 10 μm or greater is 25 or less , and the number of microparticles of 25 μm or greater is 3 or less , in 1 mL of physiological saline for injection at 3 months and 6 months after sealing the physiological saline for injection in the blood purification device.2. The blood purification device according to claim 1 , wherein the contact change rate of the porous molded body is from 0 to 0.2.3. The blood purification device according to claim 1 , wherein the porous molded body is composed of a porous molded body-forming polymer claim 1 , a hydrophilic polymer and an inorganic ion adsorbent.4. The blood purification device according to claim 3 , wherein the hydrophilic polymer is a biocompatible polymer.5. The blood purification device according to claim 4 , wherein the biocompatible polymer is a polyvinylpyrrolidone (PVP)-based polymer.6. The blood purification device according to claim 1 , wherein the porous molded body is coated with a biocompatible polymer.8. The blood purification device according to claim 7 , wherein the metal oxide is selected from among the following groups (a) to (c):(a) hydrated titanium oxide, hydrated zirconium oxide, hydrated tin oxide, ...

Sorbent And Chemical Regeneration Of Dialysate

The present invention generally relates to systems and methods for the regeneration of spent dialysis solutions. The present invention further relates to systems and methods for continuously regenerating spent dialysis solution during dialysis. The present invention further relates to systems and methods for conducting dialysis that further include using chemical and physical separators in conjunction with ion exchange cartridges and/or adsorption cartridges. 19-. (canceled)10. A method for regenerating spent dialysate comprising passing said spent dialysate , which contains urea , through at least one sorbent device capable of converting at least a portion of said urea to ammonia , and then passing said spent dialysate through a liquid-liquid counter-current extractor to remove at least a portion of said ammonia from said spent dialysate.11. The method of claim 10 , further comprising passing said spent dialysate claim 10 , after removing at least a portion of said ammonia claim 10 , through one or more subsequent sorbent devices to further purify said spent dialysate.12. The method of claim 11 , wherein said one or more subsequent sorbent devices comprise at least one cartridge capable of removing phosphate or a portion thereof claim 11 , and/or capable of removing organic uremic toxins or a portion thereof.13. The method of claim 10 , wherein said passing of said spent dialysate through said liquid-liquid counter-current extractor comprises countercurrently passing the spent dialysate containing ammonia and at least one liquid immiscible with dialysate solution containing an extractor molecule through said liquid-liquid counter-current extractor claim 10 , wherein the extractor molecule is complexed with the ammonia removed from said spent dialysate to produce a complex.14. The method of claim 13 , further comprising heating said at least one liquid and said complex after said countercurrently passing of said spent dialysate and said at least one liquid claim 13 ...

ADSORPTION CARRIER-PACKED COLUMN

An adsorption carrier-packed column includes a central pipe, adsorption carrier, plate A, and plate B, wherein an insertion material C is inserted between the adsorption carrier and the plate A; an insertion material D is inserted between the adsorption carrier and the plate B; the ratio of the deformation rate of the insertion material C (C) to the deformation rate of the adsorption carrier (E) is 1 Подробнее

Systems and methods for extracorporeal blood modification

The present invention generally relates to systems and methods for targeted removal of a substance or biomolecule such as a protein from a biological fluid, such as blood. In some cases, the blood may be withdrawn from a subject, treated, and returned to the subject. Previous techniques for removal of biological materials from blood, such as hemodialysis and plasmapheresis, were generally non-specific (i.e., they removed a multitude of proteins/toxins from the blood). By contrast, novel methods and devices described herein are capable of removing specific or single substances such as proteins from biological fluids such as blood in a specific manner. Such highly specific protein removal has a broad array of clinical applications, including treatment of inflammatory conditions and autoimmune diseases.

METHOD FOR EXTRACORPOREAL TREATMENT OF PREECLAMPSIA AND RELATED DISORDERS

A three-component composition for use in the treatment of preeclampsia and related disorders wherein a first component comprises a bimodal synthetic carbon particle mixture; a second component comprises a resin bead with at least one affinity ligand directed toward syncytiotrophoblast-derived factor sEndoglin and a third component comprises a resin bead with at least one affinity ligand directed toward syncytiotrophoblast-derived factor soluble Fms-like tyrosine kinase-1. 1. A three-component composition for use in the treatment of preeclampsia and related disorders comprising:a first component comprising a bimodal synthetic carbon particle mixture;a second component comprising a first resin bead with at least one affinity ligand directed toward syncytiotrophoblast-derived factor sEndoglin; anda third component comprising a second resin bead with at least one affinity ligand directed toward syncytiotrophoblast-derived factor soluble Fms-like tyrosine kinase-1.2. The three-component composition of wherein the components are separated.3. The three-component composition of wherein the bimodal synthetic carbon particle mixture comprises a first carbon particle having pore size x and a second carbon particle having pore size y where y is greater than x.4. (canceled)5. The three-component composition of wherein y is two times x.6. (canceled)7. The three-component composition of wherein the first resin bead claim 1 , the second resin bead claim 1 , or both the first resin bead and the second resin bead comprises gelatin claim 1 , alginate claim 1 , collagen type I claim 1 , fibrin glue claim 1 , polyglycerol sebacate (PGS) claim 1 , polyglycolic acid (PGA) claim 1 , poly-1-lactide (PLA) claim 1 , poly(lactide-co-glycolide) (PLGA) claim 1 , polyvinyl alcohol (PVA) claim 1 , polycaprolactone claim 1 , poly(N-isopropylacrylamide) claim 1 , polyethylene (PE) claim 1 , sepharose claim 1 , silica claim 1 , polyoxymethylene (POM) claim 1 , polypropylene (PP) claim 1 , ...

METHOD AND COMPOSITION FOR REMOVING UREMIC TOXINS IN DIALYSIS PROCESSES

A dialysis system comprising: a sorbent cartridge including a zirconium phosphate layer followed by at least one of a urease layer, a zirconium oxide layer, or a carbon layer; a pump in fluid communication sorbent cartridge; and a control unit in operable communication with the pump, wherein the control unit is programmed to cause the pump to pump a dialysis fluid to flow (i) in a first direction through the sorbent cartridge, wherein the zirconium phosphate layer is contacted by the dialysis fluid before the at least one of the urease layer, zirconium oxide layer or carbon layer and (ii) in a second direction through the sorbent cartridge wherein the at least one of the urease layer, zirconium oxide layer or carbon layer is contacted by the dialysis fluid before the zirconium phosphate layer. 1. A method of performing dialysis comprising:passing a dialysis fluid in a first flow direction through a sorbent cartridge in fluid communication with at least one of a patient or a dialyzer, the sorbent cartridge including a housing having a zirconium phosphate layer followed by at least one of a urease layer, a zirconium oxide layer, or a carbon layer, wherein the zirconium phosphate layer is first contacted by the dialysis fluid in the first flow direction before the at least one of the urease layer, zirconium oxide layer or carbon layer;storing the dialysis fluid in a storage container; andpassing the dialysis fluid from the storage container back through the sorbent cartridge in a reverse flow direction from the first flow direction to reach the patient or the dialyzer.2. The method of claim 1 , wherein the method is used to perform hemodialysis claim 1 , hemofiltration claim 1 , hemodiafiltration or peritoneal dialysis.3. The dialysis method of claim 1 , which includes contacting the dialysis fluid with carbon first in the reverse flow direction.4. The dialysis method of claim 1 , which includes contacting the dialysis fluid with urease as a secondary layer in the ...

The Treatment of Protein Aggregation Diseases

Compositions, methods and systems for the treatment of a protein aggregation disease including, but not limited to Alzheimer's disease (AD), Parkinson's disease (PD), Dementia with Lewy Bodies (DLB), Huntington's disease (HD), Amylotrophic lateral sclerosis (ALS, which results from degeneration of the upper and lower motor neurones and affects the voluntary muscle system), Progressive Supranuclear Palsy (PSP), Type 2 Diabetes and Multiple systems atrophy (MSA).

BLOOD PURIFICATION DEVICE

A blood purification device includes a chamber, a liquid feed line, an air introduction unit, a liquid level adjustment unit, and a control unit. The chamber is provided on a blood circuit for extracorporeally circulating patient's blood and introduces purified plasma obtained by purifying plasma separated by a plasma separator provided on the blood circuit, or a replenishing liquid for replenishing the plasma separated by the plasma separator, into the blood circuit. The liquid feed line is capable of sending the purified plasma or the replenishing liquid to the chamber. The air introduction unit is capable of introducing air into the liquid feed line. The liquid level adjustment unit is capable of adjusting a liquid level height in the chamber. At the end of blood purification treatment, the control unit performs a liquid recovery process for sending the purified plasma or the replenishing liquid to the chamber via the liquid feed line while introducing air into the liquid feed line by the air introduction unit and maintains the liquid level height in the chamber at a predetermined liquid level height by the liquid level adjustment unit. 1. A blood purification device , comprising:a chamber that is provided on a blood circuit for extracorporeally circulating patient's blood and introduces purified plasma obtained by purifying plasma separated by a plasma separator provided on the blood circuit, or a replenishing liquid for replenishing the plasma separated by the plasma separator, into the blood circuit;a liquid feed line capable of sending the purified plasma or the replenishing liquid to the chamber;an air introduction unit capable of introducing air into the liquid feed line;a liquid level adjustment unit capable of adjusting a liquid level height in the chamber; anda control unit that, at an end of blood purification treatment, performs a liquid recovery process for sending the purified plasma or the replenishing liquid to the chamber via the liquid feed line ...

CYTOPHERESIS CARTRIDGES AND USE THEREOF

The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions within a subject and to related methods. More particularly, the invention relates to a cytopheretic cartridge that includes a housing and, disposed within the housing, a solid support capable of sequestering activated leukocytes and/or platelets. 132-. (canceled)33. A method for processing an activated leukocyte , an activated platelet , or both an activated leukocyte and an activated platelet contained within a body fluid , the method comprising: (i) a rigid housing defining an inner volume (IV), a fluid inlet port and a fluid outlet port, wherein the inner volume is in fluid flow communication with the fluid inlet port and the fluid outlet port; and', {'sup': −1', '−1, '(ii) a solid support disposed within the housing and defining a fluid contacting surface with a surface area (SA) capable of sequestering an activated leukocyte and/or an activated platelet if present in a body fluid entering the housing via the fluid inlet port, wherein the cartridge has an SA/IV ratio ranging from greater than 150 cmto 800 cm; and'}], '(a) providing a cartridge comprising'}(b) introducing a body fluid from a subject into the housing via the fluid inlet port under conditions that permit sequestration of an activated leukocyte and/or an activated platelet on the fluid contacting surface of the solid support; and(c) treating the leukocyte and/or platelet sequestered in step (b) to inhibit release of a pro-inflammatory substance or to deactivate the leukocyte and/or the platelet.34. (canceled)35. The method of claim 33 , wherein the leukocyte or the platelet is sequestered for a time sufficient to inhibit the release of the pro-inflammatory substance or to deactivate the leukocyte or the platelet.36. (canceled)37. The method of claim 33 , further comprising the step of returning the leukocyte and/or the platelet produced in step (c) back to a subject.38. The method ...

Cartridge and method for increasing myocardial function

The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions that affect myocardial function and to related methods. The cartridge can be used in treating a subject with myocardial dysfunction, such as a subject with chronic heart failure and/or acute decompensated heart failure.

PLASMAPHERESIS DEVICE

A plasmapheresis device includes a column or other flow mechanism in which plasma lows following separation of the plasma from cellular components like blood cells, platelets and the like. The column includes a moiety, such as an antibody, which selectively binds to galectin-3. By removing galectin-3 from the blood stream of a mammal by at least 10%, improvements in the treatment of inflammation, suppression of the formation of fibroses, and a variety of cancer treatments can be effected or improved. The device provides tor multiple columns to remove a variety of elements but includes one which selectively removes galectin-3 from the blood flow. Other agents may be added to the plasma before recombination with the cellular components of the blood, and before returning the recombined flow to the patient. 115-. (canceled)16. A device for performing plasmapheresis , comprising:a first conduit through which blood drawn from a mammalian patient travels under the influence of a pump;a separator for separating cellular components of said blood from plasma;a column device through which said plasma flows, which said column device selectively removes a plasma component, wherein said plasma component is selected from the group consisting of a heavy metal, an autoantibody, a pesticide, a toxin, oxidized cholesterol, oxidized low density lipoprotein, a cytokine, an immunoglobulin, complement, C-reactive protein, a receptor for tumor necrosis factor α, a receptor for tumor transforming growth factor β, a receptor for nuclear factor kappa β, vascular endothelial growth factor, C-reactive protein, fibrinogen, galectin-1, galectin-3 and cytokine receptors to provide treated plasma;a second conduit which receives said treated plasma following passage in said column device and wherein said treated plasma is combined with blood cells separated in said separator prior to return to said mammalian patient;wherein said first and second conduits provide for continuous flow of said blood and ...

BLOOD CLEANSING SYSTEM

The present invention relates to removing disease material from the blood of a patient. Specifically, the invention relates to using biological binders to trap disease material that is desired to be removed from the blood of a patient. 1. A method for preparing a tube to be used for capturing disease causing material , said method comprising the steps of:activating an inner surface of the tube by treating the inner surface with substances to generate active functional groups on the inner surface of the tube;inserting into the tube a crosslinking substance such that the crosslinking substance binds to said functional group on the inner surface of the tube;inserting capturing material into the tube such that the capturing material binds to said crosslinking substance, wherein said capturing material is designed to bind to said substances.2. The method of claim 1 , wherein said tube is selected from a group comprising plastic tube claim 1 , polymer tube claim 1 , metallic tube and silicone tube.3. The method of claim 1 , wherein said substance to generate active functional groups is selected from the group comprising acidic hydrogenperoxide solution (HO:HCl:HOin 5:1:1 volume ratio) and aminopropyltrimethoxysilane (APTMS).4. The method of claim 1 , wherein said crosslinking substance is selected from the group comprising 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC or EDAC) claim 1 , sulfo-SMCC (sulfosuccinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate) claim 1 , polymer claim 1 , polymeric linker and Polyethylene Glycol (PEG).5. The method of claim 1 , wherein said capturing material is selected from the group comprising antibodies claim 1 , aptamers claim 1 , peptides claim 1 , polymers claim 1 , proteins claim 1 , nucleic acid claim 1 , RNA claim 1 , DNA claim 1 , organic materials and magnetic particles.6. The method of claim 1 , wherein said disease causing material is selected from the group comprising cancer cells claim 1 , circulating ...

BLOOD CLEANSING SYSTEM

The present invention relates to removing disease material from the blood of a patient. Specifically, the invention relates to using biological binders to trap disease material that is desired to be removed from the blood of a patient. 1. A method for removing disease causing material from blood , said method comprising the steps of:pumping blood from a patient into a cleansing apparatus;flowing said blood through said cleansing apparatus to expose said blood to a binding material;capturing disease causing material, wherein said binding material targets and binds to said disease causing material;removing said disease causing material from said blood; andreturning said blood to said patient.2. The method of claim 1 , wherein said blood is pumped to said cleansing apparatus until said cleansing apparatus is full thereby allowing said binding material to capture said disease causing material.3. The method of claim 1 , wherein said binding material is one or more binding materials selected from a group of binding materials comprising antibodies claim 1 , peptides claim 1 , proteins claim 1 , aptamers claim 1 , TNF-related apoptosis-inducing ligands (TRAIL) claim 1 , ligands claim 1 , apoptosis inducing substances claim 1 , death receptors binding substances claim 1 , tumor necrosis factors claim 1 , adhesion receptors claim 1 , E-selectin claim 1 , cytokines claim 1 , chemotherapy agents claim 1 , biological binders.4. The method of claim 1 , further comprising the step of exposing said cleansing apparatus to radiation to kill said disease causing material.5. The method of claim 1 , further comprising the step of applying heat to said cleansing apparatus to kill said disease causing material.6. The method of claim 5 , further comprising the step of cooling said cleansing apparatus to causing the cooling of said blood to a normal body temperature before returning said blood to said patient.7. The method of claim 1 , further comprising the steps of:introducing ...

Blood Cleansing System & Method

The present invention relates to removing disease material from the blood of a patient. Specifically, the invention relates to using biological binders to trap disease material that is desired to be removed from the blood of a patient. 1. A method for removing disease causing material from blood , said method comprising the steps of:attaching a photosensitizer to a binding agent to generate a conjugate material;injecting the conjugate material into a patient such that the conjugate material binds to a targeted material;circulating blood through an extracorporeal transparent tube;illuminating said tube with light to activate said photosensitizer, wherein the activation of said photosensitizer releases oxygen capable of causing cell death upon contact with the oxygen.2. The method of claim 1 , wherein said extracorporeal transparent tube is selected from a group of tubes comprising plastic tubes claim 1 , polymer tubes claim 1 , metallic tubes claim 1 , silicone tubes.3. The method of claim 1 , wherein said extracorporeal transparent tube has an inner diameter of 1.02 mm.4. The method of claim 1 , wherein said extracorporeal transparent tube is modified with one or more additional binding agents to capture said targeted material.5. The method of claim 1 , wherein said binding agent is selected from a group of binding agents comprising one or more of a an antibody claim 1 , a protein claim 1 , a peptide claim 1 , a molecule claim 1 , or one or more of a material that binds to a pathogen claim 1 , a cell claim 1 , or a cancer cell.6. The method of claim 1 , wherein said targeted material is selected from a group of targeted material comprising pathogens claim 1 , disease causing agents claim 1 , viruses claim 1 , bacteria claim 1 , fungi claim 1 , cancer cells claim 1 , stem cell-like cancer cells claim 1 , circulating tumor cells claim 1 , microbial organisms.7. The method of claim 1 , wherein said photosensitizer is modified with a crosslinker to make it receptive to ...

AGONISTIC AUTOANTIBODIES TO THE ALPHA1-ADRENERGIC RECEPTOR AND THE BETA2-ADRENERGIC RECEPTOR IN ALZHEIMER'S AND VASCULAR DEMENTIA

The invention relates to means for detecting, binding, removing and/or neutralising agonistic antibodies associated with dementia, preferably Alzheimer's disease or vascular dementia. 1. A peptide , comprising of(i) the amino acid sequence LGYWAFGRVFCN (SEQ ID No. 1) or PAPEDETICQINEE (SEQ ID No. 2);(ii) an amino acid sequence having a sequence with 70%, preferably 80% or more preferably 90% or 95% sequence identity to an amino acid sequence in accordance with (i);(iii) an amino acid sequence (i) or (ii) which is modified by branch or extension with the same or another peptide according to amino acid sequence (i) or (ii) to form a homooligomeric or heterooligomeric peptide,whereby any terminus of the peptide according to i) to iii) exhibits an additional group selected from an amino group, amide group, acetyl group, biotin group, desthio-biotin group, a marker, spacer, linker, GKK, SGKK, or no additional group.2. The peptide according to for use in medical diagnostics or as a medicament.3. The peptide according to or claim 1 ,characterized in that{'sub': 1', '2, 'the peptide binds to antibodies of patients suffering from dementia, preferably agonistic autoantibodies that bind the αadrenergic and/or the β-adrenergic receptor.'}4. An isolated nucleic acid molecule selected from the group comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a) a nucleic acid molecule consisting of a nucleotide sequence which encodes at least one peptide selected from the group consisting of peptides according to ;'}b) a nucleic acid molecule which is complementary to a nucleotide sequence in accordance with a);c) a nucleic acid molecule which undergoes hybridization with a nucleotide sequence according to a) or b) under stringent conditions;d) a nucleic acid molecule consisting of a nucleotide sequence having a sequence with 90% sequence identity to a nucleotide sequence according to a), b) or c);e) a nucleic acid molecule which, as a consequence of the genetic code, is ...

Filter and Frame Apparatus and Method of Use

Provided is a filter apparatus, comprising two or more filter cartridges having a first end with an inlet and screen and a second end with an outlet and screen, and walls to contain a filter media held in a housing for holding the two or more filter cartridges in about the same orientation, and an attachment clamp connected to the housing. Also provided is a housing for holding two or more filter cartridges in about the same orientation and a method of using the filter apparatus and housing. 120-. (canceled)21. A filter apparatus , comprising:two or more filter cartridges each having a first end with an inlet, and a first screen, a second end with an outlet and a second screen, and walls configured to contain a filter media and comprising a cartridge tube, and wherein the outlet comprises an outlet connector connected to the cartridge tube by an outlet flange;a housing comprising an upper plate and a lower plate oriented substantially parallel to each other and configured to hold the two or more filter cartridges in about the same orientation, the upper plate and the lower plate each defining two or more openings to which the two or more filter cartridges are rotatably coupled and wherein the outlet flange extends through the two or more openings of the upper plate;and an attachment clamp connected to the housing.22. The filter apparatus of claim 21 , wherein the housing further comprises one or more support elements connecting the upper plate and the lower plate.23. The filter apparatus of claim 22 , wherein the attachment clamp is connected to one or more of the one or more support elements.24. The filter apparatus of claim 22 , wherein the one or more support elements comprise a combination of rods and support plates.25. The filter apparatus of claim 21 , wherein the attachment clamp is a pole clamp.26. The filter apparatus of claim 21 , wherein the cartridge tube is comprised of a transparent material selected from the group consisting of a polysulfone claim 21 ...

DEVICE AND METHOD FOR REMOVING UNDESIRABLE BIOLOGICAL AND/OR CHEMICAL ENTITIES FROM BIOLOGICAL FLUIDS

A device for removing a biological and/or chemical entity (C) from extracorporeal blood (B) is disclosed. The device has a hollow capture chamber with an inlet for the entry of the extracorporeal blood (B) and an outlet for the outflow of the extracorporeal blood (B) and a capture element inside the capture chamber having a reactant surface placed in contact with the extracorporeal blood (B) and a plurality of binding agents (A) for the biological and/or chemical entity to be removed (C) such that the biological and/or chemical entity (C), upon exiting the capture chamber, is removed from the extracorporeal blood (B) as linked to the reactant surface. 2. The device according to claim 1 , wherein the biological and/or chemical entity to be removed (C) is a circulating tumour cell.3. The device according to claim 1 , wherein the binding agents (A) comprise one or more antibodies claim 1 , or adhesion proteins claim 1 , or aptamers claim 1 , thereby providing the removal of epithelial claim 1 , mesenchymal claim 1 , hybrid epithelial-mesenchymal claim 1 , and stem-like CTCs claim 1 , singly and/or in clusters.4. The device according to claim 1 , wherein the capture chamber has a cylindrical shape and the movable capture element extends longitudinally within the capture chamber.5. The device according to claim 1 , wherein the movable capture element is rotatable about a longitudinal axis (a) of the capture chamber.6. The device according to claim 1 , wherein the movable capture element is removable from the capture chamber.7. The device according to claim 1 , wherein the reactant surface of the movable capture element is shaped like a helix or the like.8. The device according to claim 1 , further comprising one or more conical structures having each a filtering mesh surface made of holes with a diameter equal or greater than 100 μm.9. The device according to claim 1 , wherein the plurality of binding agents (A) is distributed evenly over the entire reactant surface of ...

Systems and methods for extracorporeal blood modification

The present invention generally relates to systems and methods for targeted removal of a substance or biomolecule such as a protein from a biological fluid, such as blood. In some cases, the blood may be withdrawn from a subject, treated, and returned to the subject. Previous techniques for removal of biological materials from blood, such as hemodialysis and plasmapheresis, were generally non-specific (i.e., they removed a multitude of proteins/toxins from the blood). By contrast, novel methods and devices described herein are capable of removing specific or single substances such as proteins from biological fluids such as blood in a specific manner. Such highly specific protein removal has a broad array of clinical applications, including treatment of inflammatory conditions and autoimmune diseases.

Recovery catheter assembly

An example of recovery catheter assembly comprises an actuator element and a mechanically radially expandable and contractible recovery device operably connected to the actuator element. The recovery device has proximal and distal blocking portions and a central portion therebetween. The recovery device is at least partially placeable in a first, radially collapsed configuration and in a second, radially expanded configuration by manipulation of the actuator element. When in the second, radially expanded configuration, the proximal and distal blocking portions have radial dimensions greater than the radial dimension of the central portion thereby at least partially defining a collection chamber at the central portion.

CARTRIDGE AND METHOD FOR INCREASING MYOCARDIAL FUNCTION

The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions that affect myocardial function and to related methods. The cartridge can be used in treating a subject with myocardial dysfunction, such as a subject with chronic heart failure and/or acute decompensated heart failure. 1. A method of treating a subject having or at risk of developing chronic heart failure , the method comprising:(a) extracorporeally sequestering activated leukocytes and/or activated platelets present in a body fluid of the subject in a cartridge comprising(i) a rigid housing defining an inner volume (IV), a fluid inlet port and a fluid outlet port, wherein the inner volume is in fluid flow communication with the fluid inlet port and the fluid outlet port, and{'sup': −1', '−1', '−1, '(ii) a solid support disposed within the housing and defining a fluid contacting surface with a surface area (SA) capable of sequestering activated leukocytes and/or activated platelets, if present in a body fluid entering the housing via the fluid inlet port, wherein the SA/IV ratio of the cartridge is greater than 80 cmor is in the range from 25 cmto 2,000 cm, and the body fluid is introduced into the housing via the fluid inlet port under conditions that permit sequestration of the activated leukocytes and/or activated platelets on the fluid contacting surface of the solid support; and'}(b) treating the sequestered leukocytes and/or platelets to inhibit release of a pro-inflammatory substance or to deactivate the leukocytes and/or platelets thereby to treat or prevent chronic heart failure.2. The method of claim 1 , wherein the SA/IV ratio of the cartridge provided in step (a) is greater than 80 cm.3. The method of claim 1 , wherein the SA/IV ratio of the cartridge provided in step (a) is greater than 150 cm.45.-. (canceled)6. The method of claim 1 , wherein the solid support is disposed within the housing at a packing density in the range from 20% ...

USE OF APTAMERS IN THERAPY AND/OR DIAGNOSIS OF AUTOIMMUNE DISEASES

The present invention is directed to an aptamer comprising or consisting of the nucleic acid sequence of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and/or a nucleic acid sequence being at least 80% identical to one of SEQ ID No. 1, 2 and 3 for use in therapy and/or diagnosis of autoimmune diseases, wherein the autoimmune disease is cardiomyopathy, dilated cardiomyopathy (DCM), peripartum cardiomyopathy (PPCM), idiopathic cardiomyopathy, Chagas' cardiomyopathy, Chagas' megacolon, Chagas' megaesophagus, Chagas' neuropathy, benign prostatic hyperplasia, scleroderma, psoriasis, Raynaud syndrome, pre-eclampsia, kidney allograft rejection, myocarditis, glaucoma, hypertension, pulmonary hypertension, malignant hypertension, and/or Alzheimer's disease. 1. A method of treatment or diagnosis of autoimmune diseases , wherein an individual suffering from an autoimmune disease is administered an effective amount of an aptamer comprising a nucleic acid sequence of SEQ ID No. 1 , SEQ ID No. 2 , SEQ ID No. 3 and/or a nucleic acid sequence being at least 80% identical to one of SEQ ID No. 1 , 2 and 3 wherein autoantibodies specific for a G-protein coupled receptor are present in the serum of said individual suffering from said autoimmune disease.2. The method of claim 1 , wherein the autoimmune disease is selected from the group consisting of: cardiomyopathy claim 1 , dilated cardiomyopathy (DCM) claim 1 , peripartum cardiomyopathy (PPCM) claim 1 , idiopathic cardiomyopathy claim 1 , Chagas' cardiomyopathy claim 1 , Chagas' megacolon claim 1 , Chagas' megaesophagus claim 1 , Chagas' neuropathy claim 1 , benign prostatic hyperplasia claim 1 , scleroderma claim 1 , psoriasis claim 1 , Raynaud syndrome claim 1 , pre-eclampsia claim 1 , kidney allograft rejection claim 1 , myocarditis claim 1 , glaucoma claim 1 , Diabetes mellitus claim 1 , hypertension claim 1 , pulmonary hypertension claim 1 , malignant hypertension and Alzheimer's disease.3. The method of claim 1 , wherein an aptamer ...

BEADS FOR BLOOD PROCESSING

Provided are beads for blood processing having porous beads and a polymer carried on the surface of the porous beads, wherein: the porous beads are configured from at least one resin selected from the group consisting of acrylic resins, styrene resins, and cellulose resins; and the polymer includes a specific monomer defined in the description as a monomer unit. 2. The beads for blood processing according to claim 1 , wherein the proportion of nitrogen atoms on the surfaces of the beads for blood processing is 0.2% to 0.7% claim 1 , as the percentage of atoms based on the total number of atoms with atomic numbers of 3 to 92.3. The beads for blood processing according to claim 1 , wherein q is 1 or 2 and m is 0 to 11.4. (canceled)5. The beads for blood processing according to claim 1 , wherein the polymer further includes a charged monomer as a monomer unit.6. The beads for blood processing according to claim 5 , wherein the charged monomer is a monomer with at least one group selected from the group consisting of amino claim 5 , carboxyl claim 5 , phosphate claim 5 , sulfonate and zwitterionic groups.7. The beads for blood processing according to claim 5 , wherein the charged monomer is at least one selected from the group consisting of 2-aminoethyl methacrylate (AEMA) claim 5 , dimethylaminoethyl methacrylate (DMAEMA) claim 5 , diethylaminoethyl methacrylate (DEAEMA) claim 5 , [2-(methacryloyloxy)ethyl]trimethylammonium claim 5 , acrylic acid (AAc) claim 5 , methacrylic acid (MAc) claim 5 , N-methacryloyloxyethyl-N claim 5 ,N-dimethylammonium-α-N-methylcarboxybetaine (CMB) and 2-(methacryloyloxy)ethyl 2-(trimethylammonio)ethyl phosphate (MPC).8. The beads for blood processing according to claim 34 , wherein the content of the charged monomer is 10 mol % to 60 mol % with respect to the total monomers composing the polymer.9. The beads for blood processing according to claim 34 , wherein the content of the charged monomer is 15 mol % to 40 mol % with respect to the ...